

Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension **.rup**) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 25, 2005, 11:02:02 ; Search time 175 Seconds
(without alignments)
553.046 Million cell updates/sec

Title: US-09-823-077C-7

Perfect score: 1085
Sequence: 1 DSWMTSLNPIAGTTCVCLGON.....GPSLYSLSPSPPLPIFPC 189

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : Uniprot_03.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1060	97.7	226	2	Q6XG88 hepatitis b
2	1060	97.7	226	2	Q8BAN9 hepatitis b
3	1060	97.7	281	2	Q6XG39 hepatitis b
4	1060	97.7	389	2	Q6XG10 hepatitis b
5	1054	97.1	222	2	Q9DIY9 hepatitis b
6	1054	97.1	222	2	Q9DIY5 hepatitis b
7	1054	97.1	226	2	Q69601 hepatitis b
8	1054	97.1	226	2	Q8BAN3 hepatitis b
9	1054	97.1	226	2	Q8BAN5 hepatitis b
10	1054	97.1	226	2	Q8BAN8 hepatitis b
11	1054	97.1	226	2	Q91762 hepatitis b
12	1054	97.1	281	2	Q6XG10 hepatitis b
13	1054	97.1	281	2	Q91137 hepatitis b
14	1054	97.1	281	2	Q91136 hepatitis b
15	1054	97.1	281	2	Q91137 hepatitis b
16	1054	97.1	337	2	Q9PWY5 hepatitis b
17	1054	97.1	337	2	Q9PBR2 hepatitis b
18	1054	97.1	389	2	Q98843 hepatitis b
19	1054	97.1	389	2	Q67871 hepatitis b
20	1054	97.1	389	2	Q67879 hepatitis b
21	1054	97.1	389	2	Q6XG11 hepatitis b
22	1054	97.1	389	2	Q7T4U0 hepatitis b
23	1054	97.1	389	2	Q7T4U6 hepatitis b
24	1054	97.1	389	2	Q9PWY6 hepatitis b
25	1054	97.1	389	2	Q9WJCA hepatitis b
26	1054	97.1	400	2	Q80J12 hepatitis b
27	1051	96.9	226	2	Q8BAN9 hepatitis b
28	1050	96.8	222	2	Q9DIY9 hepatitis b
29	1050	96.8	226	2	Q8AZ60 hepatitis b
30	1050	96.8	281	2	Q41750 hepatitis b
31	1050	96.8	281	2	Q41751 hepatitis b

32	1050	96.8	281	2	Q8AYU2 hepatitis b
33	1050	96.8	370	2	Q8AZ54 hepatitis b
34	1050	96.8	389	2	Q7T4V2 hepatitis b
35	1050	96.8	389	2	Q91F39 hepatitis b
36	1049	96.7	226	2	Q67910 hepatitis b
37	1049	96.7	226	2	Q6XGK3 hepatitis b
38	1049	96.7	226	2	Q8BAN5 hepatitis b
39	1049	96.7	226	2	Q9Q3D5 hepatitis b
40	1049	96.7	226	2	Q9QAP5 hepatitis b
41	1049	96.7	281	2	Q67915 hepatitis b
42	1049	96.7	281	2	Q6XGK4 hepatitis b
43	1049	96.7	281	2	Q9QAP1 hepatitis b
44	1049	96.7	389	2	Q67886 hepatitis b
45	1049	96.7	389	2	Q67914 hepatitis b

ALIGNMENTS

RESULT 1

ID	Q6XG88	PRELIMINARY;	PRT;	226 AA.
AC	Q6XG88			
DT	05-JUL-2004 (Tremblrel. 27, Created)			
DT	05-JUL-2004 (Tremblrel. 27, Last sequence update)			
DT	05-JUL-2004 (Tremblrel. 27, Last annotation update)			
DS	S protein.			
OS	Hepatitis B virus.			
OC	Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.			
NCBI_TaxID=10407;				
RM	[1]			
RP	SEQUENCE FROM N.A.			
RX	PubMed=15105537; DOI=10.1099/vir.0.19749-0;			
RA	Kimbi G.C., Kramvis A., Kew M.C.;			
RT	"Distinctive sequence characteristics of subgenotype A1 isolates of			
RL	hepatitis B virus from South Africa."			
DR	EMBL; AY233296; AAP79871.1; -			
DR	GO; GO:0016032; P:Viral life cycle; IEA.			
DR	InterPro; IPR000349; Hepvir_surfg.			
DR	Pfam; PF00695; VMSA; 1.			
KW	Antigen.			
SO	SEQUENCE	226 AA;	25361 MW;	228209BESD7D204D CRC64;
Query Match	97.7%;	Score 1060;	DB 2;	Length 226;
Best local similarity	97.4%;	Pred. No. 2e-82;		
Matches 184;	Conservative	2;	Mismatches 3;	Indels 0;
QY	1 DSWMTSLNPIAGTTCVCLGONSQSPTSNHSPSCPTCPGTRMCLRRPIIFLFIILLCLI 60			
DB	33 DSWMTSLNPIAGTTCVCLGONSQSPTSNHSPSCPTCPGTRMCLRRPIIFLFIILLCLI 92			
QY	61 FLVILLYOGLIPVCPILPSSSTTSKGQCRCTTPAGGTMYRSCCTKPSDGNCTCPI 120			
DB	93 FLVILLYOGLIPVCPILPSSSTTSKGQCRCTTPAGGTMYRSCCTKPSDGNCTCPI 152			
QY	121 PSSWAFKYLMEWASAFWSLSPVQWPFVGLSPVWLVMMWYMGSLXSLSPF 180			
DB	153 PSSWAFKYLMEWASAFWSLSPVQWPFVGLSPVWLVMMWYMGSLXSLSPF 212			
QY	181 SPILPIFPC 189			
DB	213 SPILPIFPC 221			
RESULT 2				
Q8BAN9	PRELIMINARY;	PRT;	226 AA.	
ID	Q8BAN9			
DT	01-MAR-2003 (Tremblrel. 23, Created)			
DT	01-MAR-2003 (Tremblrel. 23, Last sequence update)			
DT	01-JUN-2003 (Tremblrel. 24, Last annotation update)			
DE	Surface antigen.			

```
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RA Bowden R.J.;
RL Submitted (OCT-2002) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Basant A.A., Bowden R.J., Butterworth L.-A., Cooksey G.,
  Locarnini S., Garman W.F.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY122559; AAM82961.1;
DR GO; GO:0016032; P:Viral life cycle; IEA.
DR InterPro; IPR000349; Hepvir_surtag.
DR Pfam; PF00695; VMSA; 1.
KW Antigen.
SQ
Query Match 226 AA; 25361 MW; 228209P95608229D CRC64;
Best Local Similarity 97.7%; Score 1060; DB 2; Length 226;
Matches 184; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTVCIGNSQSPSTNSHSPSCPTCPGRMCLRRFIIFLLILCL 60
DB 33 DSWMTSLNFIAGTTVCIGNSQSPSTNSHSPSCPTCPGRMCLRRFIIFLLILCL 92
QY 61 FLVLVDYQGLIVCPILPGSSSTTSKGQCRCTTPAAGTSMYPSCCCTKPSDGNCTCIP 120
DB 93 FLVLVDYQGLIVCPILPGSSSTTSKGQCRCTTPAAGTSMYPSCCCTKPSDGNCTCIP 152
QY 121 PSSWAFGKTYMEWASARFSLVLPVQMFVGLSPTVWLSVIMMMYMGPSLYSLISPF 180
DB 153 PSSWAFGKTYMEWASARFSLVLPVQMFVGLSPTVWLSVIMMMYMGPSLYSLISPF 212
QY 181 SPLPIFFC 189
DB 213 SPLPIFFC 221

RESULT 3
QXGXG9 PRELIMINARY; PRT; 281 AA.
AC 06XGX9;
DT 05-JUL-2004 (TEMBLrel. 27, Created)
DT 05-JUL-2004 (TEMBLrel. 27, Last sequence update)
DE Middle S protein.
DE Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RA Kimb G.C., Kramvis A., Kew M.C.;
RL Distinctive sequence characteristics of subgenotype A1 isolates of
  hepatitis B virus from South Africa."
RT J. Gen. Virol. 85:1211-1220(2004).
DR EMBL; AY233296; AAP79872.1;
DR GO; GO:0016032; P:Viral life cycle; IEA.
DR InterPro; IPR000349; Hepvir_surtag.
DR Pfam; PF00695; VMSA; 1.
KW Antigen.
SQ
Query Match 281 AA; 31206 MW; B95FEC6AD353604F CRC64;
Best Local Similarity 97.7%; Score 1060; DB 2; Length 281;
Matches 184; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTVCIGNSQSPSTNSHSPSCPTCPGRMCLRRFIIFLLILCL 60
DB 88 DSWMTSLNFIAGTTVCIGNSQSPSTNSHSPSCPTCPGRMCLRRFIIFLLILCL 147
```

```
QY 61 FLVLVDYQGLIVCPILPGSSSTTSKGQCRCTTPAAGTSMYPSCCCTKPSDGNCTCIP 120
DB 148 FLVLVDYQGLIVCPILPGSSSTTSKGQCRCTTPAAGTSMYPSCCCTKPSDGNCTCIP 207
QY 121 PSSWAFGKTYMEWASARFSLVLPVQMFVGLSPTVWLSVIMMMYMGPSLYSLISPF 180
DB 208 PSSWAFGKTYMEWASARFSLVLPVQMFVGLSPTVWLSVIMMMYMGPSLYSLISPF 267
QY 181 SPLPIFFC 189
DB 268 SPLPIFFC 276

RESULT 4
QXGXH0 PRELIMINARY; PRT; 389 AA.
AC 06XGX0;
DT 05-JUL-2004 (TEMBLrel. 27, Created)
DT 05-JUL-2004 (TEMBLrel. 27, Last sequence update)
DE Large S protein.
DE Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RA Kimb G.C., Kramvis A., Kew M.C.;
RL Distinctive sequence characteristics of subgenotype A1 isolates of
  hepatitis B virus from South Africa."
RT J. Gen. Virol. 85:1211-1220(2004).
DR EMBL; AY233296; AAP79872.1;
DR GO; GO:0016032; P:Viral life cycle; IEA.
DR InterPro; IPR000349; Hepvir_surtag.
DR Pfam; PF00695; VMSA; 1.
KW Antigen.
SQ
Query Match 389 AA; 42691 MW; CEE26773DFC603F2 CRC64;
Best Local Similarity 97.7%; Score 1060; DB 2; Length 389;
Matches 184; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTVCIGNSQSPSTNSHSPSCPTCPGRMCLRRFIIFLLILCL 60
DB 196 DSWMTSLNFIAGTTVCIGNSQSPSTNSHSPSCPTCPGRMCLRRFIIFLLILCL 255
QY 61 FLVLVDYQGLIVCPILPGSSSTTSKGQCRCTTPAAGTSMYPSCCCTKPSDGNCTCIP 120
DB 256 FLVLVDYQGLIVCPILPGSSSTTSKGQCRCTTPAAGTSMYPSCCCTKPSDGNCTCIP 315
QY 121 PSSWAFGKTYMEWASARFSLVLPVQMFVGLSPTVWLSVIMMMYMGPSLYSLISPF 180
DB 316 PSSWAFGKTYMEWASARFSLVLPVQMFVGLSPTVWLSVIMMMYMGPSLYSLISPF 375
QY 181 SPLPIFFC 189
DB 376 SPLPIFFC 384

RESULT 5
QXGDT9 PRELIMINARY; PRT; 222 AA.
AC 09DIT9;
DT 01-MAR-2001 (TEMBLrel. 16, Created)
DT 01-MAR-2001 (TEMBLrel. 16, Last sequence update)
DE Surface antigen (Fragment).
DE Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RA Liu H.F.;
```

RL Submitted (OCT-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AJ297881; CAC0278.1; -
 DR GO: GO:0016032; P:Viral life cycle; IEA.
 DR InterPro: IPR000349; Hepvit_surfAg.
 DR Pfam: PF00695; VMSA; 1.
 KW Antigen.
 FT NON TER

SEQUENCE 222 AA; 24825 MW; 9D65834D72D48FD3 CRC64;

Query Match 97.1%; Score 1054; DB 2; Length 222;
 Best Local Similarity 96.8%; Pred. No. 6.4e-82;
 Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLFGSTVTCGQNSQSPNSHSPSCPTCGYRMCARRIIFLFIILLGLI 60
 DB 33 DSWMTSLNPLFGSTVTCGQNSQSPNSHSPSCPTCGYRMCARRIIFLFIILLGLI 92
 QY 61 FLVLVDYQGLIPVCPPIPGSSTTSKQCRCTTTPAOGTSMYPSCCTKPSDGNCTCIP 120
 DB 93 FLVLVDYQGLIPVCPPIPGSSTTSKQCRCTTTPAOGTSMYPSCCTKPSDGNCTCIP 152
 QY 121 PSSNAFGKYLWEMASARPSWLSLVFVQMFVGLSPTVWLSVIMMMWTGSPSLYSILSPF 180
 DB 153 PSSNAFGKYLWEMASARPSWLSLVFVQMFVGLSPTVWLSVIMMMWTGSPSLYSILSPF 212
 QY 181 SPLLPFFC 189
 DB 213 LPLLPFFC 221

RESULT 6
 ID Q9DIV5 PRELIMINARY; PRT; 222 AA.
 AC Q9DIV5;
 DT 01-MAR-2001 (TREMBLrel. 16, Created)
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
 DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)
 DE Surface antigen (Fragment).
 OS Hepatitis B virus.
 OC Viruses; Retroviridae; Orthohepadnavirus.
 ON NCBI_TaxID=10407;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Liu H.F.;
 RL Submitted (OCT-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AJ297885; CAC0262.1; -
 DR GO: GO:0016032; P:Viral life cycle; IEA.
 DR InterPro: IPR000349; Hepvit_surfAg.
 DR Pfam: PF00695; VMSA; 1.
 KW Antigen.
 FT NON TER

SEQUENCE 222 AA; 24825 MW; 9D65834D72D48FD3 CRC64;

Query Match 97.1%; Score 1054; DB 2; Length 222;
 Best Local Similarity 96.8%; Pred. No. 6.4e-82;
 Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLFGSTVTCGQNSQSPNSHSPSCPTCGYRMCARRIIFLFIILLGLI 60
 DB 33 DSWMTSLNPLFGSTVTCGQNSQSPNSHSPSCPTCGYRMCARRIIFLFIILLGLI 92
 QY 61 FLVLVDYQGLIPVCPPIPGSSTTSKQCRCTTTPAOGTSMYPSCCTKPSDGNCTCIP 120
 DB 93 FLVLVDYQGLIPVCPPIPGSSTTSKQCRCTTTPAOGTSMYPSCCTKPSDGNCTCIP 152
 QY 121 PSSNAFGKYLWEMASARPSWLSLVFVQMFVGLSPTVWLSVIMMMWTGSPSLYSILSPF 180
 DB 153 PSSNAFGKYLWEMASARPSWLSLVFVQMFVGLSPTVWLSVIMMMWTGSPSLYSILSPF 212
 QY 181 SPLLPFFC 189
 DB 213 LPLLPFFC 221

RESULT 7

Q96601 ID Q96601 PRELIMINARY; PRT; 226 AA.
 AC Q96601;
 DT 01-NOV-1996 (TREMBLrel. 01, Created)
 DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
 DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
 DE S gene subtype aYW2 protein.
 GN Name=S gene subtype aYW2;
 OS Hepatitis B virus.
 OC Viruses; Retroviridae; Orthohepadnavirus.
 ON NCBI_TaxID=10407;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA STRAIN=genotype D;
 RC MEDLINE=92268879; PubMed=1588323;
 RX Norder H., Hammes B., Lefdel S., Courrouc A.M., Magnus L.O.;
 RT "Comparison of the amino acid sequences of nine different serotypes of
 RT Hepatitis B surface antigen and genomic classification of the
 RT corresponding hepatitis B virus strains.";
 RT J. Gen. Virol. 73:1201-1208 (1992).
 RN [2]
 RP SEQUENCE FROM N.A.
 RA STRAIN=genotype D;
 RC Norder H.M.L.;

RL Submitted (NOV-1993) to the EMBL/GenBank/DBJ databases.
 DR EMBL: X75662; CAA53349.1; -
 DR PIR: J01571; J01571.
 DR PIR: J01572; J01572.
 DR PIR: J02063; J02063.
 DR PIR: J02066; J02066.
 DR PIR: J02067; J02067.
 DR PIR: J02068; J02068.
 DR PIR: J02069; J02069.
 DR PIR: J02070; J02070.
 DR PIR: J02072; J02072.
 DR PIR: J02076; J02076.
 DR PIR: J02077; J02077.
 DR PIR: J02079; J02079.
 DR PIR: J02081; J02081.
 DR PIR: J02083; J02083.
 DR GO: GO:0016032; P:Viral life cycle; IEA.
 DR InterPro: IPR000349; Hepvit_surfAg.
 DR Pfam: PF00695; VMSA; 1.
 KW Antigen.

SEQUENCE 226 AA; 25460 MW; C68303545C6838B6 CRC64;

Query Match 97.1%; Score 1054; DB 2; Length 226;
 Best Local Similarity 96.8%; Pred. No. 6.5e-82;
 Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLFGSTVTCGQNSQSPNSHSPSCPTCGYRMCARRIIFLFIILLGLI 60
 DB 33 DSWMTSLNPLFGSTVTCGQNSQSPNSHSPSCPTCGYRMCARRIIFLFIILLGLI 92
 QY 61 FLVLVDYQGLIPVCPPIPGSSTTSKQCRCTTTPAOGTSMYPSCCTKPSDGNCTCIP 120
 DB 93 FLVLVDYQGLIPVCPPIPGSSTTSKQCRCTTTPAOGTSMYPSCCTKPSDGNCTCIP 152
 QY 121 PSSNAFGKYLWEMASARPSWLSLVFVQMFVGLSPTVWLSVIMMMWTGSPSLYSILSPF 180
 DB 153 PSSNAFGKYLWEMASARPSWLSLVFVQMFVGLSPTVWLSVIMMMWTGSPSLYSILSPF 212
 QY 181 SPLLPFFC 189
 DB 213 LPLLPFFC 221

RESULT 8

Q8BAM3 ID Q8BAM3 PRELIMINARY; PRT; 226 AA.
 AC Q8BAM3;

```
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-JUN-2003 (Tremblrel. 24, Last annotation update)
DS Surface antigen.
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OK NCBI_TaxId=10407;
RN
RP SEQUENCE FROM N.A.
RL Submitted (OCT-2002) to the EMBL/GenBank/DBJ databases.
RN
[2]
RA Basuni A.A., Bowden R.J., Butterworth L.-A., Cooksley G.,
RA Locarnini S., Carman W.F.;
RA Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY122567; AAM82977.1; -
DR GO: GO:0016032; P:Viral life cycle; IEA.
DR InterPro: IPR000349; Hepvir_surtag.
DR Pfam: PF00695; VMSA; 1.
DR Antigen.
SQ SEQUENCE 226 AA; 25359 MW; 9C60B38B9DFDC928 CRC64;

Query Match
Best Local Similarity 97.1%; Score 1054; DB 2; Length 226;
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DSWTSLNLFAGTTTCVCLGONSQSPSTNSHPTSCPTCPGGRMCLRRFIIFFLLILCLT 60
DB 33 DSWTSLNLFAGTTTCVCLGONSQSPSTNSHPTSCPTCPGGRMCLRRFIIFFLLILCLT 92
QY 61 FLVLVDYQGLFVPCPLIPGSSSTTSKGQCRCTCTTPAOGTSMYPSCCCTKPSDGNCTCIP 120
DB 93 FLVLVDYQGLFVPCPLIPGSSSTTSKGQCRCTCTTPAOGTSMYPSCCCTKPSDGNCTCIP 152
QY 121 PSSMARGKYLMEWASARFWSLSLVFVQMFVGLSPTVMLSVIWMWYMGPSLYSILSPF 180
DB 153 PSSMARGKYLMEWASARFWSLSLVFVQMFVGLSPTVMLSVIWMWYMGPSLYSILSPF 212
QY 181 SPLLPPIFFC 189
DB 213 LPLLPPIFFC 221

RESULT 9
OQBANS PRELIMINARY; PRT; 226 AA.
AC OQBANS;
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-JUN-2003 (Tremblrel. 24, Last annotation update)
DS Surface antigen.
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OK NCBI_TaxId=10407;
RN
RP SEQUENCE FROM N.A.
RL Submitted (OCT-2002) to the EMBL/GenBank/DBJ databases.
RN
[2]
RA Basuni A.A., Bowden R.J., Butterworth L.-A., Cooksley G.,
RA Locarnini S., Carman W.F.;
RA Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY122561; AAM82965.1; -
DR GO: GO:0016032; P:Viral life cycle; IEA.
DR InterPro: IPR000349; Hepvir_surtag.
DR Pfam: PF00695; VMSA; 1.
DR Antigen.
SQ SEQUENCE 226 AA; 25387 MW; B4D69BF2A626A43 CRC64;

Query Match
Best Local Similarity 97.1%; Score 1054; DB 2; Length 226;
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;
```

```
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DSWTSLNLFAGTTTCVCLGONSQSPSTNSHPTSCPTCPGGRMCLRRFIIFFLLILCLT 60
DB 33 DSWTSLNLFAGTTTCVCLGONSQSPSTNSHPTSCPTCPGGRMCLRRFIIFFLLILCLT 92
QY 61 FLVLVDYQGLFVPCPLIPGSSSTTSKGQCRCTCTTPAOGTSMYPSCCCTKPSDGNCTCIP 120
DB 93 FLVLVDYQGLFVPCPLIPGSSSTTSKGQCRCTCTTPAOGTSMYPSCCCTKPSDGNCTCIP 152
QY 121 PSSMARGKYLMEWASARFWSLSLVFVQMFVGLSPTVMLSVIWMWYMGPSLYSILSPF 180
DB 153 PSSMARGKYLMEWASARFWSLSLVFVQMFVGLSPTVMLSVIWMWYMGPSLYSILSPF 212
QY 181 SPLLPPIFFC 189
DB 213 LPLLPPIFFC 221

RESULT 10
OQBANS PRELIMINARY; PRT; 226 AA.
AC OQBANS;
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-JUN-2003 (Tremblrel. 24, Last annotation update)
DS Surface antigen.
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OK NCBI_TaxId=10407;
RN
RP SEQUENCE FROM N.A.
RL Submitted (OCT-2002) to the EMBL/GenBank/DBJ databases.
RN
[2]
RA Basuni A.A., Bowden R.J., Butterworth L.-A., Cooksley G.,
RA Locarnini S., Carman W.F.;
RA Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY122552; AAM82947.1; -
DR GO: GO:0016032; P:Viral life cycle; IEA.
DR InterPro: IPR000349; Hepvir_surtag.
DR Pfam: PF00695; VMSA; 1.
DR Antigen.
SQ SEQUENCE 226 AA; 25374 MW; 465EBE830B0EB1D CRC64;

Query Match
Best Local Similarity 96.8%; Pred. No. 6.5e-82;
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DSWTSLNLFAGTTTCVCLGONSQSPSTNSHPTSCPTCPGGRMCLRRFIIFFLLILCLT 60
DB 33 DSWTSLNLFAGTTTCVCLGONSQSPSTNSHPTSCPTCPGGRMCLRRFIIFFLLILCLT 92
QY 61 FLVLVDYQGLFVPCPLIPGSSSTTSKGQCRCTCTTPAOGTSMYPSCCCTKPSDGNCTCIP 120
DB 93 FLVLVDYQGLFVPCPLIPGSSSTTSKGQCRCTCTTPAOGTSMYPSCCCTKPSDGNCTCIP 152
QY 121 PSSMARGKYLMEWASARFWSLSLVFVQMFVGLSPTVMLSVIWMWYMGPSLYSILSPF 180
DB 153 PSSMARGKYLMEWASARFWSLSLVFVQMFVGLSPTVMLSVIWMWYMGPSLYSILSPF 212
QY 181 SPLLPPIFFC 189
DB 213 LPLLPPIFFC 221

RESULT 11
OQBANS PRELIMINARY; PRT; 226 AA.
AC OQBANS;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
```

DT 05-UTL-2004 (Tremblrel. 27, last annotation update)
DE S protein (Major surface antigen).
OC Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OK NCBI_TaxID=10407;
RN (1)
RP SEQUENCE FROM N.A.
RX MEDLINE=20109034; PubMed=10640544;
RA Hannoun C., Horal P., Linch M.;
RT "Long-term mutation rates in the hepatitis B virus genome";
J. Gen. Virol. 81:75-83(2000).
RN (2)
RP SEQUENCE FROM N.A.
RC STRAIN=438;
RX MEDLINE=20345625; PubMed=10884611; DOI=10.1016/S1286-4579(00)00365-8;
RA Barchani-Chabchoub I., Gargouri A., Mokdad-Gargouri R.;
RT "Genotyping of Tunisian hepatitis B virus isolates based on the
sequencing of pres2 and S regions";
Microbes Infect. 2:607-612(2000).
RN (3)
RP SEQUENCE FROM N.A.
RA Bowden R.J.;
RT Submitted (OCT-2002) to the EMBL/GenBank/DBJ databases.
RN (4)
RP SEQUENCE FROM N.A.
RA Basuni A.A., Bowden R.J., Butterworth L.-A., Cooksley G.,
Locarnini S., Carman W.F.;
RT Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
RN (5)
RP SEQUENCE FROM N.A.
RX PubMed=15105537; DOI=10.1099/vir.0.19749-0;
RA Kimbri G.C., Krawlis A., Kew M.C.;
RT "Distinctive sequence characteristics of subgenotype A1 isolates of
hepatitis B virus from South Africa";
J. Gen. Virol. 85:1211-1220(2004).
RN (6)
RP EMBL; AF121241; AAF24676.1; -
DR EMBL; AF229159; AAF40187.1; -
DR EMBL; AY122553; AAM82949.1; -
DR EMBL; AY122554; AAM82951.1; -
DR EMBL; AY122557; AAM82957.1; -
DR EMBL; AY122558; AAM82959.1; -
DR EMBL; AY122568; AAM82979.1; -
DR EMBL; AY122589; AAM83021.1; -
DR EMBL; AY233293; AAF79850.1; -
DR EMBL; AF21240; AAF24669.1; -
RN (7)
RP PIR; J01572; J01572.
DR PIR; J02063; J02063.
DR PIR; J02066; J02066.
DR PIR; J02067; J02067.
DR PIR; J02068; J02068.
DR PIR; J02069; J02069.
DR PIR; J02070; J02070.
DR PIR; J02072; J02072.
DR PIR; J02076; J02076.
DR PIR; J02077; J02077.
DR PIR; J02079; J02079.
DR PIR; J02081; J02081.
DR PIR; J02083; J02083.
DR PIR; J02091; J02091.
DR PIR; J02092; J02092.
DR GO; GO:0016032; P:Viral life cycle; IEA.
DR InterPro; IPR000349; Hepvir_surtag.
DR Pfam; PF00695; VMSA; 1.
KM Antigen.
SQ SEQUENCE 226 AA; 25387 MW; 228209E5D65834D CRC64;
Query Match 97.1%; Score 1054; DB 2; Length 226;
Best Local Similarity 96.8%; Pred. No. 6.5e-82;
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DSWTSLNPLFGTTVCLGNSQSPSTNSPTSCPTCPGYRMWCLARRFIIFILLCLII 60
DB 33 DSWTSLNPLFGTTVCLGNSQSPSTNSPTSCPTCPGYRMWCLARRFIIFILLCLII 92
QY 61 FLVLDYQGLPYCPILIPSSSTTSKQCRCTTPAAGTSMYBSCCTKBDGCTCIP 120
DB 93 FLVLDYQGLPYCPILIPSSSTTSKQCRCTTPAAGTSMYBSCCTKBDGCTCIP 152
QY 121 PSSWAFGKFLMEWASARFSLVLPVQWFGSLPTVMVIMMMYMGSLYSILSPF 180
DB 153 PSSWAFGKFLMEWASARFSLVLPVQWFGSLPTVMVIMMMYMGSLYSILSPF 212
QY 181 SPLLPFFC 189
DB 213 SPLLPFFC 221
RESULT 12
ID 041762 PRELIMINARY; PRT; 261 AA.
AC 041762
DT 01-JAN-1998 (Tremblrel. 05, Created)
DT 01-JAN-1998 (Tremblrel. 05, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, last annotation update)
DE Middle S protein.
GN Name=Pres2/S;
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OC NCBI_TaxID=10407;
RN (1)
RP SEQUENCE FROM N.A.
RX MEDLINE=97368435; PubMed=9225049;
RA Boyer S., van Staden L., Kew M.C., Sim J.G.;
RT "A unique segment of the hepatitis B virus group A genotype identified
in isolates from South Africa";
J. Gen. Virol. 78:1719-1729(1997).
RN (2)
RP EMBL; U87851; AAC58030.1; -
DR PIR; J01572; J01572.
DR PIR; J02063; J02063.
DR PIR; J02066; J02066.
DR PIR; J02067; J02067.
DR PIR; J02068; J02068.
DR PIR; J02069; J02069.
DR PIR; J02070; J02070.
DR PIR; J02072; J02072.
DR PIR; J02076; J02076.
DR PIR; J02077; J02077.
DR PIR; J02079; J02079.
DR PIR; J02081; J02081.
DR PIR; J02083; J02083.
DR PIR; J02091; J02091.
DR PIR; J02092; J02092.
DR GO; GO:0016032; P:Viral life cycle; IEA.
DR InterPro; IPR000349; Hepvir_surtag.
DR Pfam; PF00695; VMSA; 1.
KM Antigen.
SQ SEQUENCE 261 AA; 31338 MW; 74ADAD08B3491BC9 CRC64;
Query Match 97.1%; Score 1054; DB 2; Length 261;
Best Local Similarity 96.8%; Pred. No. 7.9e-82;
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 121 PSSWAFGKFLMEWASARFSLVLPVQWFGSLPTVMVIMMMYMGSLYSILSPF 180
DB 208 PSSWAFGKFLMEWASARFSLVLPVQWFGSLPTVMVIMMMYMGSLYSILSPF 267
QY 181 SPLLPFFC 189

Db 268 LPLPIFFC 276

RESULT 13

Q6XGU0 PRELIMINARY; PRT; 281 AA.

AC Q6XGU0; DOI=10.1099/vir.0.19749-0;

DT 05-JUL-2004 (TrEMBLrel. 27, Created)

DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)

DE Middle S protein.

OS Hepatitis B virus.

OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.

OX NCBI_TaxID=10407;

RN [1]

RP SEQUENCE FROM N.A.

RA PubMed=15105537; DOI=10.1099/vir.0.19749-0;

RA Kimb G.C., Kramvis A., Kew M.C.;

RT "Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa."

RL J. Gen. Virol. 85:1211-1220(2004).

DR EMBL; AY233293; AAP79851.1; -

DR GO; GO:0016032; P: viral life cycle; IEA.

DR InterPro; IPR000349; Hepvir_surfAg.

DR Pfam; PF00695; VMSA; 1.

KW Antigen.

SQ SEQUENCE 281 AA; 31232 MW; 52325AB26590AEF8 CRC64;

Query Match 97.1%; Score 1054; DB 2; Length 281;

Best Local Similarity 96.8%; Pred. No. 7.9e-82;

Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTTVCIGQNSQSPTSNHSPTSCPTCPGYRMCLRRFIIFLLILCL 60

DB 88 DSWMTSLNFIAGTTTVCIGQNSQSPTSNHSPTSCPTCPGYRMCLRRFIIFLLILCL 147

QY 61 FLVLLDYQGLFVCPILPGSSSTTSKGCCTCTTPAGTSMYPSCCCTKPSDNCCTCIP 120

DB 148 FLVLLDYQGLFVCPILPGSSSTTSKGCCTCTTPAGTSMYPSCCCTKPSDNCCTCIP 207

QY 121 PSSMAGKYLMEWASARFWSLSLVPFVQMFVGLSPTWLSVIMMMYMGPSLYSLSP 180

DB 208 PSSMAGKYLMEWASARFWSLSLVPFVQMFVGLSPTWLSVIMMMYMGPSLYSLSP 267

QY 181 SPLPIFFC 189

DB 268 LPLPIFFC 276

RESULT 14

Q9J1J6 PRELIMINARY; PRT; 281 AA.

AC Q9J1J6; DOI=10.1099/vir.0.19749-0;

DT 01-OCT-2000 (TrEMBLrel. 15, Created)

DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)

DE Pres2-S protein.

OS Hepatitis B virus.

OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.

OX NCBI_TaxID=10407;

RN [1]

RP SEQUENCE FROM N.A.

RA PubMed=10884611; DOI=10.1016/S1286-4579(00)00365-8;

RA Borchani-Chabchoub I., Gargouri A., Mokdad-Gargouri R.;

RT "Genotyping of Tunisian hepatitis B virus isolates based on the RT sequencing of pres2 and S regions."

RL Microbes Infect. 2:607-612(2000).

DR EMBL; AF214661; AAP31270.1; -

DR PIR; JQ1572; JQ1572.

DR PIR; JQ2063; JQ2063.

DR PIR; JQ2066; JQ2066.

DR PIR; JQ2067; JQ2067.

DR PIR; JQ2068; JQ2068.

DR PIR; JQ2069; JQ2069.

DR PIR; JQ2070; JQ2070.

DR PIR; JQ2072; JQ2072.

DR PIR; JQ2076; JQ2076.

DR PIR; JQ2077; JQ2077.

DR PIR; JQ2079; JQ2079.

DR PIR; JQ2081; JQ2081.

DR PIR; JQ2083; JQ2083.

DR PIR; JQ2091; JQ2091.

DR PIR; JQ2092; JQ2092.

DR GO; GO:0016032; P: viral life cycle; IEA.

DR InterPro; IPR000349; Hepvir_surfAg.

DR Pfam; PF00695; VMSA; 1.

KW Antigen.

FT CHAIN

SQ SEQUENCE 281 AA; 31270 MW; 673BC6C4902BF954 CRC64;

Query Match 97.1%; Score 1054; DB 2; Length 281;

Best Local Similarity 96.8%; Pred. No. 7.9e-82;

Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTTVCIGQNSQSPTSNHSPTSCPTCPGYRMCLRRFIIFLLILCL 60

DB 88 DSWMTSLNFIAGTTTVCIGQNSQSPTSNHSPTSCPTCPGYRMCLRRFIIFLLILCL 147

QY 61 FLVLLDYQGLFVCPILPGSSSTTSKGCCTCTTPAGTSMYPSCCCTKPSDNCCTCIP 120

DB 148 FLVLLDYQGLFVCPILPGSSSTTSKGCCTCTTPAGTSMYPSCCCTKPSDNCCTCIP 207

QY 121 PSSMAGKYLMEWASARFWSLSLVPFVQMFVGLSPTWLSVIMMMYMGPSLYSLSP 180

DB 208 PSSMAGKYLMEWASARFWSLSLVPFVQMFVGLSPTWLSVIMMMYMGPSLYSLSP 267

QY 181 SPLPIFFC 189

DB 268 LPLPIFFC 276

RESULT 15

Q9J1J7 PRELIMINARY; PRT; 281 AA.

AC Q9J1J7; DOI=10.1099/vir.0.19749-0;

DT 01-OCT-2000 (TrEMBLrel. 15, Created)

DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)

DE Pres2-S protein.

OS Hepatitis B virus.

OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.

OX NCBI_TaxID=10407;

RN [1]

RP SEQUENCE FROM N.A.

RA PubMed=10884611; DOI=10.1016/S1286-4579(00)00365-8;

RA Borchani-Chabchoub I., Gargouri A., Mokdad-Gargouri R.;

RT "Genotyping of Tunisian hepatitis B virus isolates based on the RT sequencing of pres2 and S regions."

RL Microbes Infect. 2:607-612(2000).

DR EMBL; AF214660; AAP31269.1; -

DR PIR; JQ1572; JQ1572.

DR PIR; JQ2063; JQ2063.

DR PIR; JQ2066; JQ2066.

DR PIR; JQ2067; JQ2067.

DR PIR; JQ2068; JQ2068.

DR PIR; JQ2069; JQ2069.

DR PIR; JQ2070; JQ2070.

DR PIR; JQ2072; JQ2072.

DR PIR; JQ2076; JQ2076.

DR PIR; JQ2077; JQ2077.

DR PIR; JQ2079; JQ2079.

DR PIR; JQ2081; JQ2081.

DR PIR; JQ2083; JQ2083.

DR PIR; JQ2091; JQ2091.

DR PIR: J02092; J02092.
 DR GO: GO:0016032; P: viral life cycle; IEA.
 DR InterPro: IPR00349; Hepvir_surfac.
 DR Pfam: PF00695; VMSA; 1.
 DR Antigen.
 KW CHAIN
 FT CHAIN
 SQ SEQUENCE 261 AA; 31260 MW; F2325C86F7D9844E CRC64;

Query Match 97.1%; Score 1054; DB 2; Length 281;
 Best local similarity 96.8%; Pred. No. 7.9e-82;
 Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy	1	DSWMTSLNPLAGSTTVCIGONSQSPTSNHSPTSCPTCPGYRMWCLRRFIIIFILLCLI	60
Db	88	DSWMTSLNPLAGSTTVCIGONSQSPTSNHSPTSCPTCPGYRMWCLRRFIIIFILLCLI	147
Qy	61	FLVLVDYQGLPVCPLIPGSSSTSKGQCRCTTPAQGTSMYPSCCCTKPSDNCCTCPI	120
Db	148	FLVLVDYQGLPVCPLIPGSSSTSKGQCRCTTPAQGTSMYPSCCCTKPSDNCCTCPI	207
Qy	121	PSSWAFGKYLWEMASARFSWLSLVPFVQMFVGLSPTVWLSYIMMMWTWGPGLYSILSPF	180
Db	208	PSSWAFGKYLWEMASARFSWLSLVPFVQMFVGLSPTVWLSYIMMMWTWGPGLYSILSPF	267
Qy	181	SPILPIFC	189
Db	268	LPLPIFC	276

Search completed: July 25, 2005, 11:24:29
 Job time : 176 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 25, 2005, 11:01:26 ; Search time 164 Seconds
(without alignments)
445.718 Million cell updates/sec

Title: US-09-823-077c-7
Perfect score: 1085
Sequence: 1 DSWWTSINFGTTCVCLGQN.....GPSLYSILSPFSLPLRIFPC 189

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_16Dec04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1054	97.1	229	6	ABP55076 Hepatitis
2	1054	97.1	347	3	ABP10596 HBV fusio
3	1046	96.4	226	4	AA62930 Amino aci
4	1046	96.4	309	7	ADG76903 Hepatitis
5	1046	96.4	389	4	AA66931 HBV genot
6	1046	96.4	389	4	AA66931 Amino aci
7	1045	96.3	226	2	AA66282 Hepatitis
8	1043	96.1	226	7	ADG6672 HBV envel
9	1041	95.9	226	7	ADG76900 Hepatitis
10	1040	95.9	226	5	AAE19897 Hepatitis
11	1040	95.9	226	5	ABW00348 Hepatitis
12	1040	95.9	249	3	AAV52545 Pan DR ep
13	1040	95.9	281	2	AAE27471 gpaag pro
14	1040	95.9	281	2	AAV32835 HBsAg Pre
15	1040	95.9	309	7	ADG76901 Hepatitis
16	1040	95.9	334	5	AAO22926 Hepatitis
17	1040	95.9	389	2	AAE22742 HBsAg-SE7
18	1040	95.9	389	2	AAE27472 lpaag pro
19	1040	95.9	389	2	AAE27474 lyl promo
20	1040	95.9	389	6	ABO10262 HBV major
21	1040	95.9	393	4	AAU14097 Hepatitis
22	1040	95.9	397	2	AAW09048 Plasmid p
23	1037	95.6	226	1	AAPO0042 Sequence
24	1037	95.6	226	2	AAE06613 Hepatitis
25	1037	95.6	371	7	ADN02610 HBV N-ter

26	1037	95.6	389	7	ADN02608 HBV pres1
27	1033	95.2	203	1	AAPI0002 Sequence
28	1033	95.2	226	1	AAPI0001 Sequence
29	1033	95.2	226	2	AAW09045 Hepatitis
30	1033	95.2	229	6	ABP55075 Hepatitis
31	1033	95.2	276	2	AAW44780 Modified
32	1033	95.2	389	6	ABP55073 Hepatitis
33	1031	95.0	226	1	AAPO0005 Sequence
34	1031	95.0	226	5	ABP77764 Amino aci
35	1030	94.9	226	5	ABP77764 Amino aci
36	1026	94.6	305	7	ADG6666 HBV envel
37	1014	93.5	325	7	ADG76917 Hepatitis
38	1010	93.1	309	7	ADG76918 Hepatitis
39	1009	93.0	197	7	ADG76914 Hepatitis
40	1007	92.8	226	2	AAE33252 HBsAg enc
41	1007	92.8	226	2	AAE5282 Deduced s
42	1007	92.8	251	2	AAE11495 RP135/HBs
43	1007	92.8	281	4	AAE02620 HBsAg pre
44	1007	92.8	389	2	AAE5287 Deduced s
45	1007	92.8	390	4	AAE02621 Chimeric

ALIGNMENTS

RESULT 1	ABP55076	standard; protein; 229 AA.
ID	ABP55076	
XX	AC	ABP55076;
XX	AC	27-JAN-2003 (first entry)
XX	DE	Hepatitis B virus wild-type small envelope protein.
XX	DE	Hepatitis B virus wild-type small envelope protein.
XX	KW	HBV; HBsAg; surface antigen; envelope; diagnosis; vaccine.
XX	OS	Hepatitis b virus.
XX	PN	W0200279217-A1.
XX	PD	10-OCT-2002.
XX	PF	26-MAR-2002; 2002MO-US009227.
XX	PR	30-MAR-2001; 2001US-00821877.
XX	PA	(ABBO) ABBOTT LAB.
XX	PI	Coleman PF, Mushahwar IA;
XX	DR	WPI; 2003-040642/03.
XX	DR	N-PSDB; ABV75785.
XX	PT	New nucleotide sequences, useful for detecting compounds that bind to
XX	PT	gp41 protein or antibodies to the Hepatitis B virus surface antigen
XX	PS	mutant or for creating primers and probes.
XX	PS	Claim 3; Fig 4A-B; 43pp; English.
XX	CC	The present sequence is the protein sequence of the small envelope
XX	CC	protein of a wild-type hepatitis B virus (HBV) subtype ayw2 strain. The
XX	CC	invention relates to a mutated HBV ayw1 strain isolated from a French
XX	CC	sample and identified as 990525169. The mutant sequence (see ABP55075)
XX	CC	contains 3 mutations compared with the wild-type sequence: substitution
XX	CC	of alanine for the threonine residue at position 123; tryptophan for
XX	CC	leucine-199; and serine for threonine-207. The T123A substitution is
XX	CC	within the 'a' determinant region and affects the H166 epitope. The
XX	CC	present invention relates to the novel HBV mutant which has a modified
XX	CC	'a' determinant as a result of T123A amino acid substitution, and to
XX	CC	methods of detecting this mutant, and/or antibodies to the mutant, in
XX	CC	patient samples. The identification and detection of mutant HBV may lead
XX	CC	to improved vaccine development and detection systems

30 Sequence 229 AA;

97.1%; Score 1054; DB 6; Length 229;

Query Match Best Local Similarity 96.8%; Pred. No. 1.2e-87; Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

1 DSWMTSLNPLGTTGTCGONSQSPSTNSHPTSCPTCPGGRMCLRRFIFLFIILCLL 60
 36 DSWMTSLNPLGTTGTCGONSQSPSTNSHPTSCPTCPGGRMCLRRFIFLFIILCLL 95
 61 FLVLADYOGILPVCPLIPSSSTTSKQCCRTCTTPAGTSMYPSCCCTKSDGCTCIP 120
 96 FLVLADYOGILPVCPLIPSSSTTSKQCCRTCTTPAGTSMYPSCCCTKSDGCTCIP 155
 121 PSSWAFFGKILWEMASARFSLVLPFVQMFVGLSPTVWLSVIMMMYWGPSLYSISPF 180
 156 PSSWAFFGKILWEMASARFSLVLPFVQMFVGLSPTVWLSVIMMMYWGPSLYSISPF 215
 181 SPLPIFFC 189
 216 LPLPIFFC 224

RESULT 2

AA10596 standard; protein; 347 AA.

AA10596;

06-AUG-2003 (revised)

08-JAN-2001 (first entry)

HBV fusion protein comprising LHB and RGD.

Fusion protein; protein coat; virus-specific packaging signal; psi; virus protein; cell permeability; cell-specific binding site; LHB; large surface protein; core antigen; gene therapy.

Hepatitis B virus. Synthetic.

MO200046376-A2.

10-AUG-2000.

04-FEB-2000; 2000MO-DE000363.

05-FEB-1999; 99DB-01004800.

(HILD/) HILD E.

Hildt E, Hofschneider P;

WPI; 2000-514959/46.

N-PSDB; AAA71734.

Particle for cell-specific gene delivery, useful in gene therapy, comprises nucleic acid in protein coat that includes a fusion protein of viral protein, permeability peptide and cell-binding site.

Claim 14; Fig 1; 34pp; German.

This invention describes a novel particle (A), comprising a protein coat with a fusion protein (FP), and, inside the coat, a nucleic acid (1) and including the sequence for a virus-specific packaging signal (psi) and a structural gene. FP contains a virus protein (VP), a peptide (P) that mediates cell permeability and a heterologous cell-specific binding site (RGD). The invention also describes (1) producing (A) in which FP contains an LHBs (large surface protein of hepatitis B virus (HBV)) and contains an HBs (hepatitis B surface protein of hepatitis B virus (HBV)) and (P) and RGD; (2) preparing (A) in which FP contains an HBV core antigen (HBCAg); (P) and RGD; (3) FP; (4) DNA encoding FP; and (5) expression vector containing the DNA of (d). The products of the invention are used in gene

CC therapy of cells and tissues, in vivo or ex vivo. This sequence CC represents a fusion protein which is described in the method of the CC invention. (updated on 06-AUG-2003 to correct OS field.)

30 Sequence 347 AA;

97.1%; Score 1054; DB 3; Length 347;

Query Match Best Local Similarity 96.8%; Pred. No. 1.9e-87; Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

1 DSWMTSLNPLGTTGTCGONSQSPSTNSHPTSCPTCPGGRMCLRRFIFLFIILCLL 60
 154 DSWMTSLNPLGTTGTCGONSQSPSTNSHPTSCPTCPGGRMCLRRFIFLFIILCLL 213
 61 FLVLADYOGILPVCPLIPSSSTTSKQCCRTCTTPAGTSMYPSCCCTKSDGCTCIP 120
 214 FLVLADYOGILPVCPLIPSSSTTSKQCCRTCTTPAGTSMYPSCCCTKSDGCTCIP 273
 121 PSSWAFFGKILWEMASARFSLVLPFVQMFVGLSPTVWLSVIMMMYWGPSLYSISPF 180
 274 PSSWAFFGKILWEMASARFSLVLPFVQMFVGLSPTVWLSVIMMMYWGPSLYSISPF 333
 181 SPLPIFFC 189
 334 LPLPIFFC 342

RESULT 3

AA62930 standard; protein; 226 AA.

AA62930;

17-SEP-2001 (first entry)

Amino acid sequence of a mutated HBV S gene antigen.

S gene; HBsAg; HBV; pre-S gene; C gene; P gene; X gene; surface antigen; envelope protein; HBsAg; HBeAg; HBCAg; DNA polymerase; reverse transcriptase; HBxAg; immune response; viral protein expression; HBV infection.

Hepatitis B virus.

MO200149828-A1.

12-JUL-2001.

05-JAN-2001; 2001MO-FR000038.

06-JAN-2000; 2000FR-00000129.

(INRM) INSERM INST NAT SANTE & RECH MEDICALE.

(INMR) BIOMERIEUX SA.

Trepo C, Mandrand B, Kay A, Chemin I, Komurian-Pradel F;

WPI; 2001-441870/47.

New mutant of hepatitis B virus, useful for diagnosis, prevention and treatment of infection, also related nucleic acids, proteins and antibodies.

Claim 36; Page 92; 102pp; French.

The present sequence represents a mutated S gene antigen, designated HBsm. It is part of the mutant hepatitis B virus (HBV) of the invention, which has a circular, partially double-stranded genome comprising pre-S, S, C, P and X genes, encoding, respectively, surface antigens, envelope protein (HBsAg), proteins HBeAg and HBCAg, DNA polymerase/reverse transcriptase, and HBxAg. The mutant HBV of the invention are used for induction of specific humoral or cellular immune responses, or antisense inhibition of viral protein expression. Proteins and nucleic acids

CC derived from mHBV (also related antibodies, vectors, transformed cells
CC and oligonucleotides) are useful for diagnosis (in standard
CC amplification, hybridization or immune-complex forming assays) and for
CC treatment of, or vaccination against, HBV infection

XX Sequence 226 AA;

Query Match 96.4%; Score 1046; DB 4; Length 226;
Best Local Similarity 95.8%; Pred. No. 6.6e-87;
Matches 181; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTVCLGNSGSPTSNHSPTSCPTCPGKRWMLRFFILFILLCLL 60
DB 33 DSWMTSLNFIAGTTVCLGNSGSPTSNHSPTSCPTCPGKRWMLRFFILFILLCLL 92
QY 61 FLVLLDYGGILPVCPILPGSSITTSKGCRTCTTPAOGTSMYPSCCCTKPSDNCCTCIP 120
DB 93 FLVLLDYGGILPVCPILPGSSITTSKGCRTCTTPAOGTSMYPSCCCTKPSDNCCTCIP 152
QY 121 PSSMARGKLTMEWASARFWSLSLVPVQWFGVLSPTWMLSVIWMWYMGPSLYSLSPF 180
DB 153 PSSMARGKLTMEWASARFWSLSLVPVQWFGVLSPTWMLSVIWMWYMGPSLYSLSPF 212
QY 181 SPILLPIFFC 189
DB 213 LPILLPIFFC 221

RESULT 4
ADG76903
ID ADG76903 standard; protein; 309 AA.

XX ADG76903;

DT 11-MAR-2004 (first entry)

XX Hepatitis B virus envelope amino acid sequence Segid26.

XX hepatitis B virus; HBV; polymerase; ADV; LMV, TTV, FTC, ADV; LMV, ADV,
XX TTV; anti-HBV agent; hepatotropic; virucide; anti-inflammatory;
XX HBV variant polymerase-antagonist; gene therapy; viral component;
XX inhibiting infection; virus replication; virus release; envelope.

XX Hepatitis B virus.

XX Key Location/Qualifiers
FH Misc-difference 1..309
FT /label= OTHER
PT /note= "OTHER= Any Xaa's in this sequence can be any
amino acid"

XX WO2003087351-A1.

XX 23-OCT-2003.

XX 11-APR-2003; 2003WO-AU000432.

XX 12-APR-2002; 2002AU-00001710.

XX 26-JUN-2002; 2002AU-00003224.

XX (MELB-) MELBOURNE HEALTH.

XX (AUST-) AUSTIN & REPARIATION MEDICAL CENT.

XX (SHEA-) SOUTHERN HEALTH.

XX Bartholomew AI, Locarnini SA, Ayres A, Colledge D, Sasadeusz J;
PI Tillmann H, Angus PW, Stevert W;

XX WPI; 2003-845324/78.

XX New isolated hepatitis B viral variants with reduced susceptibility to
PT nucleoside analogs, useful for screening, designing and/or developing
PT agents capable of inhibiting infection, replication and/or release of the
PT virus.

XX Example 5; SEQ ID NO. 26; 268pp; English.

XX This invention relates to a novel isolated hepatitis B virus (HBV)
XX variant which comprises a nucleoside mutation in a gene encoding a DNA
XX polymerase resulting in at least one amino acid addition, substitution
XX and/or deletion to the polymerase, and exhibiting decreased sensitivity
XX to (for example) ADV, LMV, TTV, or FTC, or ADV and LMV, ADV and TTV,
XX and/or other nucleoside, analogues, anti-HBV agents or their
XX combinations. The invention may be useful for the development of
XX compounds with a hepatotropic, virucide or anti-inflammatory activity as
XX HBV variant polymerase-antagonists. In addition, the sequences may be
XX useful for gene therapy. The HBV variants or their component are useful
XX in the rational design of an anti-HBV agent comprising microarray
XX analysis and is based on the crystal structure or NMR structure of a
XX viral component. The methods and compositions of the present invention
XX are also useful for screening, designing and/or developing agents capable
XX of inhibiting infection, replication and/or release of the virus.

XX Sequence 309 AA;

Query Match 96.4%; Score 1046; DB 7; Length 309;
Best Local Similarity 96.3%; Pred. No. 9.1e-87;
Matches 182; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTVCLGNSGSPTSNHSPTSCPTCPGKRWMLRFFILFILLCLL 60
DB 116 DSWMTSLNFIAGTTVCLGNSGSPTSNHSPTSCPTCPGKRWMLRFFILFILLCLL 175
QY 61 FLVLLDYGGILPVCPILPGSSITTSKGCRTCTTPAOGTSMYPSCCCTKPSDNCCTCIP 120
DB 176 FLVLLDYGGILPVCPILPGSSITTSKGCRTCTTPAOGTSMYPSCCCTKPSDNCCTCIP 235
QY 121 PSSMARGKLTMEWASARFWSLSLVPVQWFGVLSPTWMLSVIWMWYMGPSLYSLSPF 180
DB 236 PSSMARGKLTMEWASARFWSLSLVPVQWFGVLSPTWMLSVIWMWYMGPSLYSLSPF 295
QY 181 SPILLPIFFC 189
DB 296 LPILLPIFFC 304

RESULT 5

XX AAG66931
ID AAG66931 standard; protein; 389 AA.

XX AAG66931;

XX 19-OCT-2001 (first entry)

XX HBV genotype D pres1/pres2/HBsAg polypeptide.

XX Hepatitis B virus; HBV; preCore; Core; pres1; pres2; HBs; HBx; HBp1;
XX HBsAg; antiviral; vaccine; genotype G; genotyping; HBcAg; HBsAg.

XX Hepatitis B virus.

XX WO200140279-A2.

XX 07-JUN-2001.

XX 20-NOV-2000; 2000WO-EP011526.

XX 03-DEC-1999; 99EP-00870252.

XX 07-DEC-1999; 99US-0169287P.

XX (INNO-) INNOGENETICS NV.

XX Stuyver L, Van Geyt C, De Gendt S;

XX WPI; 2001-374785/39.

XX Novel isolated and/or purified hepatitis B virus polypeptide and

PT polynucleotide sequences that are phylogenetically different from HBV
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
therapy.

Example 3, Fig 6, 94pp; English.

The invention relates to the complete nucleic acid sequence of a new
human hepatitis B virus (HBV) genotype, provisionally named genotype G.
This genotype was found with a high prevalence in patients chronically
infected with HBV and residing in Europe and the USA. The invention
relates to a fully defined sequence of 3248 nucleotides as given in
specification, a sequence with 92% identity to the given sequence, or
sequence that is degenerate to the mentioned sequences. These
polynucleotides are useful for HBV genotyping. The proteins encoded by
the polynucleotides are useful for detecting antibodies in a biological
sample. Ligands that bind to the proteins and antibodies directed against
the proteins are useful for detecting the proteins and for detecting
HBsAg and HBeAg (precursor proteins). They are also useful for
preparing a vaccine or medicament for treating HBV infections. The
present sequence is provided in an amino acid sequence alignment of the
preS1, preS2 and HBeAg open reading frame of the different HBV genotypes

XX SQ Sequence 389 AA;

Query Match 96.4%; Score 1046; DB 4; Length 389;
Best Local Similarity 96.3%; Pred. No. 1.2e-86;
Matches 182; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTCVCLGQNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLLFILLCL 60
DB DSWMTSLNFIAGTTCVCLGQNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLLFILLCL 255
QY 61 FLVLVDYQGLIPVCPILPGSSTTSKGCRCCTTTPAOGTSMYPSCCTKPSDGNCTCIP 120
DB FLVLVDYQGLIPVCPILPGSSTTSKGCRCCTTTPAOGTSMYPSCCTKPSDGNCTCIP 315
QY 121 PSSNAFGKYLWEMASARPSWLSLVPFQVFGSLPTVWLSVIMMMWTMGPSLYSILSPF 180
DB PSSNAFGKYLWEMASARPSWLSLVPFQVFGSLPTVWLSVIMMMWTMGPSLYSILSPF 375
QY 181 SPLLPFPFC 189
DB 376 LPLLPFPFC 384

RESULT 6
AA62931
ID AAG62931 standard; protein; 389 AA.

XX AC AAG62931;

XX DT 17-SEP-2001 (first entry)

XX DE Amino acid sequence of a mutated HBV Pre-S protein.

XX S gene; HBem; mHBV; HBV; pre-S gene; C gene; P gene; X gene;
XX surface antigen; envelope protein; HBeAg; HBsAg; DNA polymerase;
XX reverse transcriptase; HBxAg; immune response; viral protein expression;
XX HBV infection.

XX OS Hepatitis B virus.

XX PN WO200149828-A1.

XX PD 12-JUL-2001.

XX PF 05-JAN-2001; 2001WO-FR000038.

XX PR 06-JAN-2000; 2000FR-00000129.

XX PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
XX (INRM) BIOMERIEUX SA.

PI Trepo C, Mandrand B, Kay A, Chemin I, Komurian-Pradel F,
XX WPI; 2001-441870/47.

PT New mutant of hepatitis B virus, useful for diagnosis, prevention and
PT treatment of infection, also related nucleic acids, proteins and
PT antibodies.

XX PS Claim 36; Page 92-94; 102pp; French.

The present sequence represents a mutated Pre-S gene. It is part of the
mutant hepatitis B virus (mHBV) of the invention, which has a circular,
partially double-stranded genome comprising pre-S, S, C, P and X genes,
encoding, respectively, surface antigens, envelope protein (HBsAg),
proteins HBeAg and HBxAg, DNA polymerase/reverse transcriptase, and
HBxAg. The mutant HBV of the invention are used for induction of specific
humoral or cellular immune responses, or antisense inhibition of viral
protein expression. Proteins and nucleic acids derived from mHBV (also
related antibodies, vectors, transformed cells and oligonucleotides) are
useful for diagnosis (in standard amplification, hybridization or immune-
complex forming assays) and for treatment of, or vaccination against, HBV
infection.

XX SQ Sequence 389 AA;

Query Match 96.4%; Score 1046; DB 4; Length 389;
Best Local Similarity 95.8%; Pred. No. 1.2e-86;
Matches 181; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTCVCLGQNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLLFILLCL 60
DB DSWMTSLNFIAGTTCVCLGQNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLLFILLCL 255
QY 61 FLVLVDYQGLIPVCPILPGSSTTSKGCRCCTTTPAOGTSMYPSCCTKPSDGNCTCIP 120
DB FLVLVDYQGLIPVCPILPGSSTTSKGCRCCTTTPAOGTSMYPSCCTKPSDGNCTCIP 315
QY 121 PSSNAFGKYLWEMASARPSWLSLVPFQVFGSLPTVWLSVIMMMWTMGPSLYSILSPF 180
DB PSSNAFGKYLWEMASARPSWLSLVPFQVFGSLPTVWLSVIMMMWTMGPSLYSILSPF 375
QY 181 SPLLPFPFC 189
DB 376 LPLLPFPFC 384

RESULT 7
AA62826
ID AAW62826 standard; protein; 226 AA.

XX AC AAW62826;

XX DT 26-OCT-1998 (first entry)

XX DE Hepatitis B virus surface antigen.

XX Hepatitis delta virus; L-HBsg; virus-like particle; infection;
XX Hepatitis B surface antigen; HBeAg; immunogen; vaccine.

XX OS Hepatitis B virus.

XX PN WO9828004-A1.

XX PD 02-JUL-1998.

XX PF 24-DEC-1997; 97WO-AU000884.

XX PR 24-DEC-1996; 96AU-00004341.

XX PA (QUEB-) QUEBENS LAND DEPT HEALTH SAKZEMSKI VIRUS.

XX PI Gowans EJ, Macnaughton TB;

DR .WPI; 1998-377411/32.
DR N-PSDB; AAV42306.

PT Virus-like particle for, e.g. treating microbial infection - comprises
PT polypeptide from microorganism and sequence from Hepatitis B virus large
PT protein, partially enveloped by Hepatitis B surface antigen.

XX Example; Fig 6; 72pp; English.

XX This polypeptide comprises a hepatitis B virus surface antigen (HBsAg)
CC encoded by the DNA insert (see AAV42306) of plasmid pTM-HBsAg. The
CC invention provides a virus-like particle (VLP) comprising an antigenic
CC and/or immunogenic polypeptide from a microorganism (e.g. hepatitis C
CC virus) fused to at least the last 19 amino acids (see AAV62827) of the C-
CC terminal sequence of the large protein from hepatitis B virus (L-HBsAg),
CC in which the fusion protein is packaged into VLPS through the interaction
CC of the L-HBsAg moiety with HBsAg. The VLP is used to ameliorate or protect
CC against infections caused by hepatitis B virus and/or another
CC microorganism.

CC Sequence 226 AA;

Query Match 96.3%; Score 1045; DB 2; Length 226;
Best Local Similarity 95.8%; Pred. No. 8.1e-87;
Matches 181; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 DSWMTSLNLTGTTVCLGNSQSPSTNSHPTSCPPCPGGRMCLRRFIFLILLCL 60
DB 33 DSWMTSLNLTGTTVCLGNSQSPSTNSHPTSCPPCPGGRMCLRRFIFLILLCL 92
QY 61 FLVLVDYQGLIPVCPILPGSSSTTSKQCRCTTPAQTSMYPSCCCTKPSDNCICPI 120
DB 93 FLVLVDYQGLIPVCPILPGSSSTTSKQCRCTTPAQTSMYPSCCCTKPSDNCICPI 152
QY 121 PSSWAFGKYLMEVNASRFSWLSLVFPVQMFVGLSPTVWLSVIMMMYWGSPSLYSILSPF 180
DB 153 PSSWAFGKYLMEVNASRFSWLSLVFPVQMFVGLSPTVWLSVIMMMYWGSPSLYSILSPF 212
QY 181 SPLLPFFC 189
DB 213 LPLLPFFC 221

RESULT 8

ADG06672
ID ADG06672 standard; protein; 226 AA.

AC ADG06672;

DT 18-DEC-2003 (first entry)

DE HBV envelope gene protein from patient B on-ETV therapy.

XX HBV; entecavir; ETV; lamivudine((-)-beta-2'-deoxy-3'-thiacytidine);

XX lamivudine; LMV; 3TC; virucide; antiinflammatory; hepatotropic;

XX nucleoside analogue resistance; vaccine; HBsAg; envelope;

XX surface antigen.

OS Hepatitis B virus.

XX MO2003066841-A1.

PD 14-AUG-2003.

PF 05-FEB-2003; 2003MO-AU000111.

PR 07-FEB-2002; 2002AU-00000370.

XX 21-MAR-2002; 2002AU-00001269.
XX (MELB-) MELBOURNE HEALTH.
XX (AUST-) AUSTIN & REPARATION MEDICAL CENT.
XX (SHBA-) SOUTHERN HEALTH.

PI Bartholomewsz AI, Locarnini SA, Ayres A, Angus PW, Sievert W;
XX WPI; 2003-663592/62.

PT New variants of hepatitis B virus resistant to nucleoside analogs, useful
PT in vaccines and for screening to detect therapeutic inhibitors.

XX Example 5; Fig 10; 124pp; English.

XX The invention relates to a novel isolated hepatitis B virus (HBV) variant
CC comprising a nucleoside mutation in a DNA polymerase gene resulting in at
CC least one amino acid addition, substitution and/or deletion, where the
CC variant has reduced sensitivity to entecavir (ETV) or lamivudine((-)-beta
CC -2'-deoxy-3'-thiacytidine) (LMV or 3TC). The variant of the invention
CC demonstrates virucide, antiinflammatory and hepatotropic activities and
CC may be useful for treating and monitoring nucleoside analogue-resistant
CC HBV infections, in screening for therapeutic agents or in the rational
CC design of such agents, as well as in the design of vaccines. The current
CC sequence is that of the HBV envelope gene protein (HBsAg; Hepatitis B
CC surface antigen) of the invention which was isolated from patient B
CC during ETV therapy.

XX Sequence 226 AA;

Query Match 96.1%; Score 1043; DB 7; Length 226;
Best Local Similarity 95.2%; Pred. No. 1.2e-86;
Matches 180; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DSWMTSLNLTGTTVCLGNSQSPSTNSHPTSCPPCPGGRMCLRRFIFLILLCL 60
DB 33 DSWMTSLNLTGTTVCLGNSQSPSTNSHPTSCPPCPGGRMCLRRFIFLILLCL 92
QY 61 FLVLVDYQGLIPVCPILPGSSSTTSKQCRCTTPAQTSMYPSCCCTKPSDNCICPI 120
DB 93 FLVLVDYQGLIPVCPILPGSSSTTSKQCRCTTPAQTSMYPSCCCTKPSDNCICPI 152
QY 121 PSSWAFGKYLMEVNASRFSWLSLVFPVQMFVGLSPTVWLSVIMMMYWGSPSLYSILSPF 180
DB 153 PSSWAFGKYLMEVNASRFSWLSLVFPVQMFVGLSPTVWLSVIMMMYWGSPSLYSILSPF 212
QY 181 SPLLPFFC 189
DB 213 LPLLPFFC 221

RESULT 9

ADG76900
ID ADG76900 standard; protein; 226 AA.

AC ADG76900;

DT 11-MAR-2004 (first entry)

DE Hepatitis B virus envelope amino acid sequence SeqID23.

XX hepatitis B virus; HBV; polymerase; ADV; LMV; TV; FTC; ADV; LMV; ADV;

XX TV; anti-HBV agent; hepatotropic; virucide; antiinflammatory;

XX HBV variant polymerase-antagonist; gene therapy; viral component;

XX inhibiting infection; virus replication; virus release; envelope.

OS Hepatitis B virus.

XX Key Location/Qualifiers

PD Misc-difference 1. 226

PF /label= OTHER

XX /note= "OTHER= Any Xaa's in this sequence can be any
XX amino acid"

XX MO2003087351-A1.
XX 23-OCT-2003.
XX 11-APR-2003; 2003MO-AU000432.

XX 12-APR-2002; 2002AU-00001710.
PR 26-JUN-2002; 2002AU-00003224.
XX
XX (MELB-) MELBOURNE HEALTH.
PA (AUST-) AUSTIN & REPARATION MEDICAL CENT.
XX (SHEA-) SOUTHERN HEALTH.
XX Bartholomewus AI, Locarnini SA, Ayres A, Colledge D, Sasadeusz J,
PI Tilmann H, Angus PW, Stevert W,
XX WPI; 2003-845324/78.
DR
XX New isolated hepatitis B viral variants with reduced susceptibility to
PT nucleoside analogs, useful for screening, designing and/or developing
PT agents capable of inhibiting infection, replication and/or release of the
PT virus.
XX
XX Example 5; SEQ ID NO 23; 268bp; English.
XX
XX This invention relates to a novel isolated hepatitis B virus (HBV)
CC variant which comprises a nucleoside mutation in a gene encoding a DNA
CC polymerase resulting in at least one amino acid addition, substitution
CC and/or deletion to the polymerase, and exhibiting decreased sensitivity
CC to (for example) ADV, LMV, TFM, or FIC, or ADV and LMV, ADV and TFM,
CC and/or other nucleoside analogues, anti-HBV agents or their
CC combinations. The invention may be useful for the development of
CC compounds with a hepatocytotropic, virucide or anti-inflammatory activity as
CC HBV variant polymerase-antagonists. In addition, the sequences may be
CC useful for gene therapy. The HBV variants or their component are useful
CC in the rational design of an anti-HBV agent comprising microarray
CC analysis and is based on the crystal structure or NMR structure of a
CC viral component. The methods and compositions of the present invention
CC are also useful for screening, designing and/or developing agents capable
CC of inhibiting infection, replication and/or release of the virus.
XX
SQ Sequence 226 AA;
XX
Query Match 95.9%; Score 1041; DB 7; Length 226;
Best Local Similarity 95.8%; Pred. No. 1.9e-86;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
XX
QY 1 DSWMTSLNFIAGTTCVCGNSQSPSTNSHSPSCPTCPGYRMCLRRFIIFLLICLI 60
DB 33 DSWMTSLNFIAGTTCVCGNSQSPSTNSHSPSCPTCPGYRMCLRRFIIFLLICLI 92
QY 61 FLVLADYQGIILVPCPLIPSSSTTSKGCRTCTTAAQSTSMYPSGCCCKRSDGCTCIP 120
DB 93 FLVLADYQGMILVPCPLIPSSSTTSKGCRTCTTAAQSTSMYPSGCCCKRSDGCTCIP 152
QY 121 PSSWAARGKTYMWAASARFWSLSSLPVQWFGVLSPTVWLSVIMMMYMGPSLYSILSPF 180
DB 153 PSSWAARGKTYMWAASARFWSLSSLPVQWFGVLSPTVWLSVIMMMYMGPSLYSILSPF 212
QY 181 SPFLPIFFC 189
DB 213 LPFLPIFFC 221
XX
RESULT 10
AAE19897
ID AAE19897 standard; protein; 226 AA.
XX
XX AAE19897;
AC
XX 18-JUN-2002 (first entry)
DT
XX Hepatitis B virus S antigen (HBsAg) sequence.
DE
XX Hepatitis B virus; HBV; infection; virucide; fungicide; antibacterial;
KM cytosolic; immunostimulant; vaccine; ribavirin; immune response; cancer.
XX Hepatitis B virus.
OS

XX WO200213855-A2.
FN
XX 21-FEB-2002.
PD
XX
XX 15-AUG-2001; 2001WO-IB001808.
PR
XX 17-AUG-2000; 2000US-0225767P.
PR 29-AUG-2000; 2000US-0229175P.
PR 03-NOV-2000; 2000US-00705547.
XX
XX (TRIP-) TRIP AB.
XX
XX Salberg M, Hultgren C;
PI
XX WPI; 2002-241837/29.
DR
XX
XX Vaccine compositions for treating and preventing disease, preferably
PT hepatitis C virus infection, comprises ribavirin and antigen that has
PT epitope present in hepatitis C virus.
XX
XX Claim 11; Page 81; 120bp; English.
XX
XX The invention relates to a composition comprising ribavirin and an
CC antigen preferably non structural 3 protein (NS3)/4A fragment of HCV
CC hepatitis C virus (HCV) genome or a peptide or nucleic acid of HCV
CC sequence. The composition is useful for enhancing an immune response to a
CC hepatitis C antigen in humans, domestic, sport or pet species and as
CC vaccines for treating and preventing HCV infections. The composition is
CC also useful for treating viral, bacterial, fungal diseases and cancer.
XX The present sequence is Hepatitis B virus S antigen (HBsAg) sequence
XX
SQ Sequence 226 AA;
XX
Query Match 95.9%; Score 1040; DB 5; Length 226;
Best Local Similarity 95.8%; Pred. No. 2.3e-86;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
XX
QY 1 DSWMTSLNFIAGTTCVCGNSQSPSTNSHSPSCPTCPGYRMCLRRFIIFLLICLI 60
DB 33 DSWMTSLNFIAGTTCVCGNSQSPSTNSHSPSCPTCPGYRMCLRRFIIFLLICLI 92
QY 61 FLVLADYQGIILVPCPLIPSSSTTSKGCRTCTTAAQSTSMYPSGCCCKRSDGCTCIP 120
DB 93 FLVLADYQGMILVPCPLIPSSSTTSKGCRTCTTAAQSTSMYPSGCCCKRSDGCTCIP 152
QY 121 PSSWAARGKTYMWAASARFWSLSSLPVQWFGVLSPTVWLSVIMMMYMGPSLYSILSPF 180
DB 153 PSSWAARGKTYMWAASARFWSLSSLPVQWFGVLSPTVWLSVIMMMYMGPSLYSILSPF 212
QY 181 SPFLPIFFC 189
DB 213 LPFLPIFFC 221
XX
RESULT 11
ABW00348
ID ABW00348 standard; protein; 226 AA.
XX
XX ABW00348;
AC
XX 15-JAN-2004 (first entry)
DT
XX Hepatitis B virus S antigen (HBsAg).
DE
XX Ribavirin; vaccine; immune response; infection; therapy; immunostimulant;
KM virucide.
XX
XX Hepatitis B virus.
OS
XX US2002136740-A1.
PN
XX 26-SEP-2002.
PD

XX 15-AUG-2001; 2001US-00929955.
 XX 17-AUG-2000; 2000US-0225767P.
 XX 29-AUG-2000; 2000US-0229175P.
 XX (SALL/) SALLBERG M.
 XX (HULT/) HULTBERG C.
 XX Sallberg M, Hultgren C,
 XX WPI; 2003-764978/72.
 XX
 XX Vaccination compositions for treating and preventing disease, preferably
 XX hepatitis C virus infection, comprises ribavirin and antigen that has
 XX epitope present in hepatitis C virus.
 XX
 XX Claim 11; Page 44; Opp; English.
 XX
 XX The invention relates to a composition comprising ribavirin and an
 XX antigen, where the antigen is derived from a hepatitis virus. The vaccine
 XX is useful in enhancing the immune response to a hepatitis C antigen where
 XX the composition is delivered to an animal identified as requiring an
 XX enhanced immune response. The vaccine is useful in the treatment and
 XX prevention of hepatitis C infection. The present sequence is Hepatitis B
 XX virus S antigen (HBsAg)
 XX
 XX Sequence 226 AA;
 XX
 XX Query Match 95.9%; Score 1040; DB 7; Length 226;
 XX Best Local Similarity 95.8%; Pred. No. 2.3e-86;
 XX Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
 XX
 XX 1 DSWMTSLNLTGTTVCLGNSGSPSTNSHPTSCPTCPGYNMCLRRFIFILLICLI 60
 XX 33 DSWMTSLNLTGTTVCLGNSGSPSTNSHPTSCPTCPGYNMCLRRFIFILLICLI 92
 XX
 XX 61 FLVLVDYGGILPVCPGLIPGSSSTTSKGQCRCTCTTPAOGTSMYSCCTCPSDNCTCIP 120
 XX 93 FLVLVDYGGMLPVCPGLIPGSSSTTSKGQCRCTCTTPAOGTSMYSCCTCPSDNCTCIP 152
 XX
 XX 121 PSSMARGKTLMEASARFSLVLPVQVGLSPTVWLSVIMMMYMGPSLXSLSP 180
 XX 153 PSSMARGKTLMEASARFSLVLPVQVGLSPTVWLSVIMMMYMGPSLXSLSP 212
 XX
 XX 181 SPLLPFFC 189
 XX 213 LPLLPFFC 221
 XX
 XX RESULT 12
 XX AAY52545
 XX ID AAY52545 standard; protein; 249 AA.
 XX
 XX AAY52545;
 XX
 XX 06-AUG-2003 (revised)
 XX 28-FEB-2000 (first entry)
 XX
 XX Pan DR epitope/HSV surface antigen fusion protein.
 XX
 XX Chimeric; HBV, surface antigen; pan DR epitope; expression vector;
 XX promoter; major histocompatibility complex; MHC; targeting; peptide;
 XX epitope; antigen; presentation; class I; cytotoxic pathway;
 XX endoplasmic reticulum; class II; extracellular antigen;
 XX endocytic pathway; helper T lymphocyte; HTL; universal epitope;
 XX cytotoxic T lymphocyte; CTL; immune response; immunogenicity; assay;
 XX vaccine; immunity; infection; pathogen; virus; HIV; HBV; HCV;
 XX hepatitis B; hepatitis C; bacterium; protozoan; tumour cell;
 XX autoimmune disease; activation; antiviral; antimalarial;
 XX immunoprotective.
 XX
 XX Synthetic.

XX Hepatitis B virus.
 XX WO958658-A2.
 XX 18-NOV-1999.
 XX 13-MAY-1999; 99WO-US010646.
 XX 13-MAY-1998; 98US-00078904.
 XX 15-MAY-1998; 98US-0085751P.
 XX (EPTM-) EPTMONE INC.
 XX
 XX Fikes JD, Hermanson GQ, Sette A, Ishloka GY, Livingston B;
 XX Cheenut RW;
 XX WPI; 2000-039103/03.
 XX N-PDDB; AAZ8623.
 XX
 XX Expression vectors encoding major histocompatibility targeting sequence,
 XX used as, e.g. tumor vaccines.
 XX
 XX Example 1; Fig 8; 130pp; English.
 XX
 XX This sequence represents the fusion protein encoded by a pan DR
 XX epitope/HSV surface antigen fusion gene, PADRE-HBV-s, used in an
 XX exemplification of the present invention. The invention relates to a
 XX novel expression vector comprising a promoter operably linked to a fusion
 XX gene encoding a major histocompatibility complex (MHC) targeting
 XX sequence, and two or more heterologous peptide epitopes. The MHC
 XX targeting sequence may be a class I targeting sequence, which directs
 XX an MHC class I epitope to a cytosolic pathway or to the endoplasmic
 XX reticulum, or an MHC class II targeting sequence, which directs
 XX extracellular antigens to enter the endocytic pathway to be processed
 XX into antigen peptides for presentation on MHC class II molecules. The
 XX heterologous epitopes may comprise either helper T lymphocyte (HTL)
 XX epitopes, or a cytotoxic T lymphocyte (CTL) epitope and a universal HTL
 XX epitope such as a pan DR epitope (PADRE). The vectors are useful for
 XX stimulating an immune response in vivo, as well as for use in assaying
 XX the human immunogenicity of a human T cell peptide epitope in vivo in a
 XX non-human mammal. They provide a nucleic acid vaccine for enhancing
 XX immunity against infectious pathogens, such as viruses (e.g., HIV,
 XX hepatitis B (HBV) and hepatitis C (HCV)), bacteria, protozoa (e.g.,
 XX Plasmodium falciparum, the cause of malaria) and also tumour cells and
 XX autoimmune diseases. Universal MHC class II epitopes are advantageously
 XX combined with other MHC class I and class II epitopes to increase the
 XX number of cells that are activated in response to a given antigen and
 XX provide a broader population coverage of MHC-reactive alleles. (Updated
 XX on 06-AUG-2003 to correct OS field.)
 XX
 XX Sequence 249 AA;
 XX
 XX Query Match 95.9%; Score 1040; DB 3; Length 249;
 XX Best Local Similarity 95.8%; Pred. No. 2.5e-86;
 XX Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
 XX
 XX 1 DSWMTSLNLTGTTVCLGNSGSPSTNSHPTSCPTCPGYNMCLRRFIFILLICLI 60
 XX 56 DSWMTSLNLTGTTVCLGNSGSPSTNSHPTSCPTCPGYNMCLRRFIFILLICLI 115
 XX
 XX 61 FLVLVDYGGILPVCPGLIPGSSSTTSKGQCRCTCTTPAOGTSMYSCCTCPSDNCTCIP 120
 XX 116 FLVLVDYGGMLPVCPGLIPGSSSTTSKGQCRCTCTTPAOGTSMYSCCTCPSDNCTCIP 175
 XX
 XX 121 PSSMARGKTLMEASARFSLVLPVQVGLSPTVWLSVIMMMYMGPSLXSLSP 180
 XX 176 PSSMARGKTLMEASARFSLVLPVQVGLSPTVWLSVIMMMYMGPSLXSLSP 235
 XX
 XX 181 SPLLPFFC 189
 XX 236 LPLLPFFC 244
 XX

RESULT 13
 AAR27471
 ID AAR27471 standard; protein; 281 AA.
 XX
 AC AAR27471;
 XX
 DT 25-MAR-2003 (revised)
 DT 24-FEB-1993 (first entry)
 XX
 DE sBsaAg protein.
 XX
 KW Hepatitis B virus; HBV; M protein; small pre-S antigen; sBsaAg;
 KW vaccinia virus; H6; early/late; promoter; NVAC; recombinant; HBV L,
 KW large pre-S antigen; lBsaAg; fusion protein; pre-S region; S12/core; S1;
 KW S2; Copenhagen vaccine strain; vaccinia virus; virulence factor;
 KW deletion loci; recipient loci.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Region 1..55
 FT /label= S2
 FT 56..281
 FT Region /label= S
 XX
 PN W09215672-A1.
 XX
 PD 17-SEP-1992.
 XX
 PF 09-MAR-1992; 92WO-US001906.
 XX
 PR 07-MAR-1991; 91US-00666056.
 PR 11-JUN-1991; 91US-00713967.
 PR 06-MAR-1992; 92US-00847951.
 XX
 PA (VIBRO-) VIBROGENETICS CORP.
 XX
 PI Paolletti E, Perkins ME, Taylor J, Tartaglia J, Norton EK,
 PI Riviere M, De Taisne C, Limbach KJ, Johnson GP, Pincus SE, Cox WJ,
 PI Francis J, Gettig RR;
 DR WPI: 1992-331718/40.
 DR N-PSDB; MAQ29103.
 XX
 PT Vaccine comprises recombinant, attenuated pox-virus - use for vaccinating
 PT against viral infections such as rabies, hepatitis B, HIV, HSV, EBV, CMV,
 PT mumps etc.
 XX
 PS Disclosure; Fig 9; 456pp; English.
 XX
 CC The sequence given is encoded by an expression cassette which consists of
 CC the hepatitis B virus (HBV) M protein (small pre-S antigen, sBsaAg) gene
 CC precisely linked to a modified synthetic vaccinia virus H6 early/late
 CC promoter. This DNA sequence was used in the construction of a NVAC
 CC recombinant expressing the HBV gene. Other HBV genes were also used in
 CC the construction. These were HBV L (large pre-S antigen, lBsaAg) and a
 CC fusion protein composed of the entire pre-S region (S12/core, S1 + S2).
 CC Each of these gene sequences were inserted individually into three
 CC different sites of NVAC separated by from each other by large regions of
 CC vaccinia DNA containing essential genes. NVAC is a Copenhagen vaccine
 CC strain of vaccinia virus which has been modified by deletion of six non-
 CC essential regions of the genome encoding known or potential virulence
 CC factors. The deletion loci were engineered as recipient loci for the
 CC insertion of foreign genes. The spacing of the three inserted sequences
 CC ensured that any recombination that did occur would lead to disruption of
 CC the vaccinia genome and would cause unviable vaccinia virus. See also
 CC MAQ35501-864. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 281 AA;
 Query March 95.9%; Score 1040; DB 2; Length 281;
 Best Local Similarity 95.8%; Pred. No. 2.9e-86;
 Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLAGTTCVCGONQSPPTSNHSPPTSCPTCGCYWMCARPIIFLILLCL 60
 DB 88 DSWMTSLNPLAGTTCVCGONQSPPTSNHSPPTSCPTCGCYWMCARPIIFLILLCL 147
 QY 61 FLVLLDYQGLIPVCPILIPGSSITSSKQCCRTCTTTPAQTSMYPSCCCTPBDGNTCTCPI 120
 DB 148 FLVLLDYQGLIPVCPILIPGSSITSSKQCCRTCTTTPAQTSMYPSCCCTPBDGNTCTCPI 207
 QY 121 PPSWAFGKYLWEMASARPSWLSLVPVQWFGVLSPTVWLSVIMMMYWGSLYSILSPF 180
 DB 208 PPSWAFGKYLWEMASARPSWLSLVPVQWFGVLSPTVWLSVIMMMYWGSLYSILSPF 267
 QY 181 SPLPLPFC 189
 DB 268 LPLPLPFC 276
 RESULT 14
 AAY32835
 ID AAY32835 standard; protein; 281 AA.
 XX
 AC AAY32835;
 XX
 DT 27-AUG-2003 (revised)
 DT 29-OCT-1999 (first entry)
 XX
 DE HBsaAg PreS2-S region protein sequence.
 XX
 KW HBsaAg; PreS2-S; recombinant antigen library; disease-related antigen;
 KW multivalent antigenic polypeptide production; infection; allergen;
 KW asthma; autoimmune disease; rheumatoid arthritis; diabetes; therapy;
 KW multiple sclerosis; inflammatory condition; cancer; contraception;
 KW immune response; hepatitis b surface antigen.
 XX
 OS Hepatitis B virus.
 XX
 PN W09941383-A1.
 XX
 PD 19-AUG-1999.
 XX
 PF 10-FEB-1999; 99WO-US002944.
 XX
 PR 11-FEB-1998; 98US-00021769.
 PR 11-FEB-1998; 98US-0074294P.
 PR 23-OCT-1998; 98US-0105509P.
 XX
 PA (MAXY-) MAXYGEN INC.
 XX
 PI Punnonen J, Baas SH, Whalen RG, Howard R, Stemmer WPC;
 DR WPI: 1999-518452/43.
 DR N-PSDB; MAZ10968.
 XX
 PT Recombinant multivalent antigenic polypeptide produced by recombining
 PT nucleic acid sequences and screening, used in vaccines against e.g.
 PT infections and cancer.
 XX
 PS Example 14; Fig 17; 153pp; English.
 XX
 CC This sequence is the hepatitis B virus (HBV) surface antigen (HBsaAg)
 CC PreS2-S region. This sequence was used to create a recombinant antigen
 CC library. The library comprises recombinant nucleic acids encoding
 CC antigenic polypeptides and is produced by recombination of at least two
 CC forms of nucleic acid, differing by at least two nucleotides, encoding a
 CC disease-related antigenic polypeptide. The library can be used to produce
 CC a recombinant multivalent antigenic polypeptides of the invention, that
 CC contains at least two antigenic determinants (AD) from different
 CC polypeptides. The multivalent antigenic polypeptides are used in vaccines
 CC to induce a protective or therapeutic response to a wide variety of
 CC infectious agents (bacteria, viruses, parasites, including Plasmodium
 CC falciparum); allergens; asthma; autoimmune disease (e.g. rheumatoid
 CC arthritis, diabetes, multiple sclerosis); other inflammatory conditions

CC and cancer, also, where directed against sperm antigens, they can be used
CC for contraception. The multivalent peptides can be evolved to induce an
CC optimized immune response against a wide variety of antigens,
CC particularly a broad spectrum response to many different strains of a
CC pathogen, including strains that are likely to appear in the future.
CC (Updated on 27-AUG-2003 to correct OS field.)
CC
XX

XX Sequence 281 AA;

Query Match 95.9%; Score 1040; DB 2; Length 281;

Best Local Similarity 95.8%; Pred. No. 2.9e-86; Indels 0; Gaps 0;

Matches 181; Conservative 2; Mismatches 6;

QY 1 DSMWTSINFLGGTTVCLGQNSQSPTSNHSPTSCPTCPGKRWMLRRFIPIFILLCUI 60

DB 88 DSMWTSINFLGGTTVCLGQNSQSPTSNHSPTSCPTCPGKRWMLRRFIPIFILLCUI 147

QY 61 FLVVLDDYQGLIPVCPPLIPGSSITTSKQCRCTCTPAQGTSMYPSCCCTPSPDNCCTCIP 120

DB 148 FLVVLDDYQGLIPVCPPLIPGSSITTSKQCRCTCTPAQGTSMYPSCCCTPSPDNCCTCIP 207

QY 121 PSSMAFGKYLMEWASARFWSLSLVFPVQWFGLSPTVWLSYIMMMWYGPISLISLSPF 180

DB 208 PSSMAFGKYLMEWASARFWSLSLVFPVQWFGLSPTVWLSYIMMMWYGPISLISLSPF 267

QY 181 SPLLPFFC 189

DB 268 LPLLPFFC 276

RESULT 15

ADG76901 standard; protein; 309 AA.

ID ADG76901

AC ADG76901;

DT 11-MAR-2004 (first entry)

DE Hepatitis B virus envelope amino acid sequence SegID24.

KM hepatitis B virus; HBV; polymerase; ADV; LMV; TVF; FIC; ADV; LMV; ADV;

KM TVF; anti-HBV agent; hepatocarcinoma; virucide; anti-inflammatory;

KM HBV variant polymerase-antagonist; gene therapy; viral component;

OS Hepatitis B virus.

PN WO2003087351-A1.

PD 23-OCT-2003.

PF 11-APR-2003; 2003WO-AU000432.

PR 12-APR-2002; 2002AU-00001710.

PR 26-JUN-2002; 2002AU-00003224.

PA (MELB-) MELBOURNE HEALTH.

PA (AUST-) AUSTIN & REPARATION MEDICAL CENT.

PA (SHEA-) SOUTHERN HEALTH.

PI Barchi-Jomeaux AI, Locarnini SA, Ayres A, Colledge D, Sasadenuez J,

PI Tiliemann H, Angus PM, Stever W;

DR WPI; 2003-845324/78.

XX New isolated hepatitis B viral variants with reduced susceptibility to
XX nucleoside analogs, useful for screening, designing and/or developing
XX agents capable of inhibiting infection, replication and/or release of the
XX virus.
XX Example 5; SEQ ID NO 24; 268bp; English.
XX This invention relates to a novel isolated hepatitis B virus (HBV)
CC

CC variant which comprises a nucleoside mutation in a gene encoding a DNA
CC polymerase resulting in at least one amino acid addition, substitution
CC and/or deletion to the polymerase, and exhibiting decreased sensitivity
CC to (for example) ADV, LMV, TVF, or FIC, or ADV and LMV, ADV and TVF,
CC and/or other nucleoside, analogues, anti-HBV agents or their
CC combinations. The invention may be useful for the development of
CC compounds with a hepatocarcinoma, virucide or anti-inflammatory activity as
CC HBV variant polymerase-antagonists. In addition, the sequences may be
CC useful for gene therapy. The HBV variants or their component are useful
CC in the rational design of an anti-HBV agent comprising microarray
CC analysis and is based on the crystal structure or NMR structure of a
CC viral component. The methods and compositions of the present invention
CC are also useful for screening, designing and/or developing agents capable
CC of inhibiting infection, replication and/or release of the virus.
CC
XX

XX Sequence 309 AA;

Query Match 95.9%; Score 1040; DB 7; Length 309;

Best Local Similarity 95.8%; Pred. No. 3.2e-86; Indels 0; Gaps 0;

Matches 181; Conservative 2; Mismatches 6;

QY 1 DSMWTSINFLGGTTVCLGQNSQSPTSNHSPTSCPTCPGKRWMLRRFIPIFILLCUI 60

DB 116 DSMWTSINFLGGTTVCLGQNSQSPTSNHSPTSCPTCPGKRWMLRRFIPIFILLCUI 175

QY 61 FLVVLDDYQGLIPVCPPLIPGSSITTSKQCRCTCTPAQGTSMYPSCCCTPSPDNCCTCIP 120

DB 176 FLVVLDDYQGLIPVCPPLIPGSSITTSKQCRCTCTPAQGTSMYPSCCCTPSPDNCCTCIP 235

QY 121 PSSMAFGKYLMEWASARFWSLSLVFPVQWFGLSPTVWLSYIMMMWYGPISLISLSPF 180

DB 236 PSSMAFGKYLMEWASARFWSLSLVFPVQWFGLSPTVWLSYIMMMWYGPISLISLSPF 295

QY 181 SPLLPFFC 189

DB 296 LPLLPFFC 304

Search completed: July 25, 2005, 11:21:29
Job time : 166 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

3M protein - protein search, using SW model

Run on: July 25, 2005, 11:13:41 / Search time 39 Seconds
(without alignments)
466.281 Million cell updates/sec

Title: US-09-823-077C-7
Perfect score: 1085
Sequence: 1 DSWMTSLNPLGTTVCIGQON.....GPSYSLSPSPPLPIFFC 189

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: PIR 79: *
1: pirl1: *
2: pirl2: *
3: pirl3: *
4: pirl4: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1054	97.1	226	1 JQ1571	major surface anti
2	1054	97.1	389	1 SAVLBN	large surface anti
3	1054	97.1	389	1 S20745	surface antigen -
4	1054	97.1	389	1 S20753	surface antigen -
5	1050	96.8	226	2 JQ2077	surface antigen -
6	1050	96.8	226	2 JQ2076	surface antigen -
7	1049	96.7	226	2 JQ2078	surface antigen -
8	1047	96.5	226	2 JQ2079	surface antigen -
9	1046	96.4	226	2 JQ2075	surface antigen -
10	1046	96.4	226	2 JQ2073	surface antigen -
11	1046	96.4	389	2 S32202	large surface anti
12	1044	96.2	226	2 JQ2069	surface antigen -
13	1043	96.1	226	2 JQ2081	surface antigen -
14	1041	95.9	389	1 S47407	surface antigen -
15	1040	95.9	226	1 JQ1572	major surface anti
16	1040	95.9	226	2 JQ2065	surface antigen -
17	1040	95.9	226	2 JQ2067	surface antigen -
18	1040	95.9	226	2 JQ2083	surface antigen -
19	1040	95.9	389	1 SAVLBN	large surface anti
20	1037	95.6	226	2 JQ2066	surface antigen -
21	1037	95.6	226	2 JQ2063	surface antigen -
22	1037	95.6	389	1 SAVLBN	large surface anti
23	1037	95.6	389	1 SAVLBN	large surface anti
24	1036	95.5	226	2 JQ2068	surface antigen -
25	1031	95.0	226	2 JQ2070	surface antigen -
26	1030	94.9	226	2 JQ2080	surface antigen -
27	1027	94.7	226	2 JQ2072	surface antigen -
28	1017	93.7	226	2 JQ2050	surface antigen -
29	1016	93.6	226	2 JQ2092	surface antigen -

30	1012	93.3	226	2 JQ2085	surface antigen -
31	1010	93.1	226	2 JQ2054	surface antigen -
32	1007	92.8	226	2 JQ1573	major surface anti
33	1007	92.8	226	2 JQ2052	surface antigen -
34	1007	92.8	226	2 JQ2055	surface antigen -
35	1007	92.8	226	2 JQ2045	surface antigen -
36	1007	92.8	389	2 S41871	surface antigen -
37	1007	92.8	400	1 JQ1575	major surface anti
38	1007	92.8	400	1 SAVLBN	large surface anti
39	1006	92.7	226	2 JQ2087	surface antigen -
40	1006	92.7	226	2 JQ2089	surface antigen -
41	1006	92.7	226	2 JQ2090	surface antigen -
42	1006	92.7	226	2 JQ2091	surface antigen -
43	1005	92.6	226	1 JQ1577	major surface anti
44	1005	92.6	226	1 JQ1578	major surface anti
45	1004	92.5	226	1 SAVLBN	major surface anti

ALIGNMENTS

RESULT 1

JQ1571
Major surface antigen - hepatitis B virus (subtype ayw2)

C/Species: hepatitis B virus, HBV
A/Note: host Homo sapiens (man)

C/Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 09-Jul-2004
C/Accession: JQ1571; JQ2074

R/Number: H.; Hammas, B.; Loeferl, S.; Courouce, A.M.; Magnus, L.O.
U. Gen. Virol. 73, 1201-1208, 1992

A/Title: Comparison of the amino acid sequences of nine different serotypes of hepatitis B
A/Reference number: JQ1570; MUID:92268879; PMID:1588323

A/Accession: JQ1571
A/Molecule type: DNA

A/Residues: 1-226 <NO2>
A/Cross-References: UNIPROT:Q69601; GB:X75662; NID:G416086; PIDN:CAA53349.1; PID:G416087

A/Experimental source: subtype ayw2, strain P2
J. Nordier, H.; Hammas, B.; Lee, S.D.; Bille, K.; Courouce, A.M.; Mushahwar, I.K.; Magnus, L.O.
J. Gen. Virol. 74, 1341-1348, 1993

A/Title: Genetic relatedness of hepatitis B viral strains of diverse geographical origin
A/Reference number: JQ2044; MUID:93329382; PMID:8336122

A/Contents: genogroup D
A/Accession: JQ2074

A/Molecule type: DNA
A/Residues: 1-226 <NO2>

A/Experimental source: subtype ayw2, strain Ren
C/Genetics:

A/Gene: S
C/Superfamily: hepatitis B virus surface antigen

C/Keywords: glycoprotein; surface antigen
P/3/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 97.1% Score 1054; DB 1; Length 226;
Best Local Similarity 96.8%; Pred. No. 2.5e-77;
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY	1	DSWMTSLNPLGTTVCIGQONSPSTNSHSPSCPTCGGYRMCLRRFTIFPIILLICI	60
DB	33	DSWMTSLNPLGTTVCIGQONSPSTNSHSPSCPTCGGYRMCLRRFTIFPIILLICI	92
QY	61	FLVVLDDYQGLPVCPLIPGSSSTTSKQCRCTTPAOGTSMYPSCCCTKPSDGNCTCIP	120
DB	93	FLVVLDDYQGLPVCPLIPGSSSTTSKQCRCTTPAOGTSMYPSCCCTKPSDGNCTCIP	152
QY	121	PSNNAFGKYLWEMASARFSSWLSLVPYQWFGVLSPTWLSVTMMMTWGPSLYISLSPF	180
DB	153	PSNNAFGKYLWEMASARFSSWLSLVPYQWFGVLSPTWLSVTMMMTWGPSLYISLSPF	212
QY	181	SPILPIFFC 189	
DB	213	SPILPIFFC 221	

RESULT 2

SAVLBH

Large surface antigen - hepatitis B virus (subtype ayw, strain PHB320)
N/Contains: major surface antigen; middle surface antigen
C/Species: hepatitis B virus, HBV
A/Note: Host Homo sapiens (man)
C/Date: 17-Mar-1987 #sequence_revision 17-Mar-1987 #text_change 09-Jul-2004
C/Accession: A03704, P00585
R/Bichko, V.; Pashko, P.; Drellina, D.; Pumpen, P.; Gren, E.
FEBS Lett. 185, 208-212, 1985

A/Title: Subtype ayw variant of hepatitis B virus: DNA primary structure analysis.
A/Reference number: A05237; M01D:85204397; PMID:3996597
A/Accession: A03704
A/Molecule type: DNA
A/Residues: 1-389 <BIG>
A/Cross-references: UNIPROT:Q9WJG4; GB:X02496; NID:g62280; P1DN:CAH41701.1; PID:g4704321

R/Norder, H.; Courouce, A.M.; Magnius, L.O.
U. Gen. Virol. 73, 3141-3145, 1992
A/Title: Molecular basis of hepatitis B virus serotype variations within the four major
A/Reference number: P00453; M01D:93107848; PMID:1469353
A/Accession: P00585
A/Molecule type: DNA
A/Residues: 264-343 <NOR>
A/Experimental source: subtype ayw2, Tav

C/Genetics:
A/Gene: pre-S1/pre-S2/S
C/Superfamily: hepatitis B virus surface antigen
C/Keywords: glycoprotein, surface antigen
F/109-389/Product: middle surface antigen (gene pre-S2/S) #status predicted <DSA>
F/164-389/Product: major surface antigen (gene S) #status predicted <MSA>
F/164-112,166/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 97.1%; Score 1054; DB 1; Length 389;
Best Local Similarity 96.8%; Pred. No. 3.8e-77;
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DSWMTSLNPLGTTVCLGQNSQSPNSHPTSCPTCPGKRWKCLRRFIIFLLILCL 60
Db 196 DSWMTSLNPLGTTVCLGQNSQSPNSHPTSCPTCPGKRWKCLRRFIIFLLILCL 255
Qy 61 FLVLVDYQGLIPVCPPIPGSSSTTSKQCRCTCTPAQGTSMYPSCCCTKPSDGNCTCPI 120
Db 256 FLVLVDYQGLIPVCPPIPGSSSTTSKQCRCTCTPAQGTSMYPSCCCTKPSDGNCTCPI 315
Qy 121 PSSMAFGKYLWEMASARFSLSLVFPVQWFGVLSPTVWLSYIMMMYWGSPSLYSILSPF 180
Db 316 PSSMAFGKYLWEMASARFSLSLVFPVQWFGVLSPTVWLSYIMMMYWGSPSLYSILSPF 375
Qy 181 SPLLPFFC 189
Db 376 LPLLPFFC 384

RESULT 3

S20745

surface antigen - hepatitis B virus (subtype ayw, patient C)
N/Alternate names: Hbs antigen
N/Contains: surface antigen pre-S1 (large envelope protein); surface antigen pre-S2 (mid

C/Species: hepatitis B virus, HBV
A/Variety: subtype ayw, patient C
C/Date: 20-Feb-1995 #sequence_revision 01-Nov-1996 #text_change 09-Jul-2004
C/Accession: S20745
R/Lai, M.B.; Mazzoleni, A.P.; Balestrieri, A.; Wells, A.; Porru, A.
Submitted to the EMBL Data Library, March 1992

A/Description: Sequence analysis of HBV genomes isolated from patients with HBeAg negati
A/Reference number: S20745
A/Accession: S20745
A/Molecule type: DNA
A/Residues: 1-389 <LAI>

A/Cross-references: UNIPROT:Q67871; EMBL:X65257; NID:g59429; P1DN:CAA46349.1; PID:g59430
A/Experimental source: subtype ayw, patient C
C/Genetics:
A/Gene: S

C/Superfamily: hepatitis B virus surface antigen
C/Keywords: surface antigen
F/1-389/Product: surface antigen pre-S1 (large envelope protein) #status predicted <PS1>
F/1-108/Domain: pre-S1 domain #status predicted <PRB1>
F/109-389/Product: surface antigen pre-S2 (middle envelope protein) #status predicted
F/109-163/Domain: pre-S2 domain #status predicted <PRB2>
F/164-389/Product: surface antigen S (small envelope protein) #status predicted <PSD>

Query Match 97.1%; Score 1054; DB 2; Length 389;
Best Local Similarity 96.8%; Pred. No. 3.8e-77;
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DSWMTSLNPLGTTVCLGQNSQSPNSHPTSCPTCPGKRWKCLRRFIIFLLILCL 60
Db 196 DSWMTSLNPLGTTVCLGQNSQSPNSHPTSCPTCPGKRWKCLRRFIIFLLILCL 255
Qy 61 FLVLVDYQGLIPVCPPIPGSSSTTSKQCRCTCTPAQGTSMYPSCCCTKPSDGNCTCPI 120
Db 256 FLVLVDYQGLIPVCPPIPGSSSTTSKQCRCTCTPAQGTSMYPSCCCTKPSDGNCTCPI 315
Qy 121 PSSMAFGKYLWEMASARFSLSLVFPVQWFGVLSPTVWLSYIMMMYWGSPSLYSILSPF 180
Db 316 PSSMAFGKYLWEMASARFSLSLVFPVQWFGVLSPTVWLSYIMMMYWGSPSLYSILSPF 375
Qy 181 SPLLPFFC 189
Db 376 LPLLPFFC 384

RESULT 4

S20753

surface antigen - hepatitis B virus (subtype ayw, patient E)
N/Alternate names: envelope protein, Hbs antigen
N/Contains: surface antigen pre-S1 (large envelope protein); surface antigen pre-S2 (m

C/Species: hepatitis B virus, HBV
A/Variety: subtype ayw, patient E
C/Date: 20-Feb-1995 #sequence_revision 01-Nov-1996 #text_change 09-Jul-2004
C/Accession: S20753
R/Lai, M.B.; Mazzoleni, A.P.; Balestrieri, A.; Wells, A.; Porru, A.
Submitted to the EMBL Data Library, March 1992

A/Description: Sequence analysis of HBV genomes isolated from patients with HBeAg negat
A/Reference number: S20745
A/Accession: S20753
A/Molecule type: DNA
A/Residues: 1-389 <LAI>

A/Cross-references: UNIPROT:Q67879; EMBL:X65259; NID:g59439; P1DN:CAA46357.1; PID:g59444
A/Experimental source: subtype ayw, patient E
C/Genetics:
A/Gene: S
C/Superfamily: hepatitis B virus surface antigen
C/Keywords: surface antigen
F/1-389/Product: surface antigen pre-S1 (large envelope protein) #status predicted <PS1>
F/1-108/Domain: pre-S1 domain #status predicted <PRB1>
F/109-389/Product: surface antigen pre-S2 (middle envelope protein) #status predicted
F/109-163/Domain: pre-S2 domain #status predicted <PRB2>
F/164-389/Product: surface antigen S (small envelope protein) #status predicted <PSD>

Query Match 97.1%; Score 1054; DB 2; Length 389;
Best Local Similarity 96.8%; Pred. No. 3.8e-77;
Matches 183; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DSWMTSLNPLGTTVCLGQNSQSPNSHPTSCPTCPGKRWKCLRRFIIFLLILCL 60
Db 196 DSWMTSLNPLGTTVCLGQNSQSPNSHPTSCPTCPGKRWKCLRRFIIFLLILCL 255
Qy 61 FLVLVDYQGLIPVCPPIPGSSSTTSKQCRCTCTPAQGTSMYPSCCCTKPSDGNCTCPI 120
Db 256 FLVLVDYQGLIPVCPPIPGSSSTTSKQCRCTCTPAQGTSMYPSCCCTKPSDGNCTCPI 315
Qy 121 PSSMAFGKYLWEMASARFSLSLVFPVQWFGVLSPTVWLSYIMMMYWGSPSLYSILSPF 180
Db 316 PSSMAFGKYLWEMASARFSLSLVFPVQWFGVLSPTVWLSYIMMMYWGSPSLYSILSPF 375

Db 256 FVLVLVDYQGMPLPCPIIPSSSTTSAGPCRCCTTTAGTSMYBPCCCCTKSDGNCCTCPI 315
QY 121 PSEGAARCKYIMENASAPFSWLSILVPEVQWVGISLPTVWLSVIMMMYKQPSYLSILSP 180
Db 316 PSSMAFGATLMEHNASAPFSWLSILVPEVQWVGISLPTVWLSVIMMMYKQPSYLSILSP 375
QY 181 SPLLPITFFC 189
Db 376 LPLLPITFFC 384

RESULT 12

surface antigen - hepatitis B virus (subtype ayw4, strain 17798/73)
 C/Specties: hepatitis B virus, HBV
 C/Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 09-Jul-2004
 C/Accession: JQ2065
 R/Norcedn: H.; Hammans, B.; Lee, S.D.; Bile, K.; Courouce, A.M.; Mushawar, I.K.; Magnus
 J. Gen. Virol. 74, 1341-1348, 1993
 A/Title: Genetic relatedness of hepatitis B viral strains of diverse geographical origin
 A/Reference number: JQ2064; PMID:93329382; PMID:8336122
 A/Contents: genomgroup D
 A/Accession: JQ2069
 A/Molecule type: DNA
 A/Residues: 1-226 <NOR>
 A/Cross-references: UNIPROT:Q9J139; UNIPROT:Q9J1J8; UNIPROT:Q9J1T5; UNIPROT:Q9J1B9; UNIPROT:Q9J1F3; UNIPROT:Q9J190; UNIPROT:Q9Q382; UNIPROT:Q9B6U0; UNIPROT:Q9WHR3; UNIPROT:Q952; UNIPROT:Q980; UNIPROT:Q67917; UNIPROT:Q9QAG3; UNIPROT:Q998M0; UNIPROT:Q69600; UNIPROT:Q8BAF4; UNIPROT:Q9J1T5
 C/Genetics:
 A/Genes: S
 C/Superfamily: hepatitis B virus surface antigen
 C/Keywords: surface antigen

Query Match	96.2%	Score 1044;	DB 2;	Length 226;
Best Local Similarity	96.3%	Pred. No. 1.6e-76;		
Matches 182; Conservative	2;	Mismatches 5;	Indels 0;	Gaps 0

QY	1	DSWMTSLNFGTTCVCLGQNSQSPTSNHSPTSCPTCGYRMCCRRFIIFFILLCLH	60
DB	33	DSWMTSLNFGTTCVCLGQNSQSPTSNHSPTSCPTCGYRMCCRRFIIFFILLCLH	92
QY	61	FLVLVDYQGILPVCPII PGSSSTTSKGOCCRTCTTPAQGTSMPTSCCCTTSPBDNCCTIPI	120
DB	93	FLVLVDYQGMLPVCPII PGSSSTTSSTGCRCTTIAQGTSMPTSCCCTTSPBDNCCTIPI	152
QY	121	PGSMARCKTLMENASARPSNLSLVPTVQWPTGLSPTVWLSTVIMMMWYMGPSLYSLSP	180
DB	153	PGSMARCKTLMENASARPSNLSLVPTVQWPTGLSPTVWLSTVIMMMWYMGPSLYSLSP	212
QY	181	SPLLPIFFC	189
DB	213	LPILLPIFFC	221

RESULT 13

JQ2081
surface antigen - hepatitis B virus (subtype ayw2, strain PHBV38)
C:Species: hepatitis B virus, HBV
C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 09-Jul-2004
C:Accession: JQ2081
R:Border: H.; Hammas, B.; Lee, S.D.; Bille, K.; Courouce, A.M.; Mushawar, I.K.; Magnus,
J.: Gen. Virol. 74, 1341-1348, 1993
A:Title: Genetic relatedness of hepatitis B viral strains of diverse geographical origin
A:Reference number: JQ2044; PMID:9329382; PMID:8336122
A:Contents: genomgroup D
A:Accession: JQ2081
A:Molecule type: DNA
A:Residues: 1-226 <NR>
A:Cross-references: UNIPROT:O8OXK3; UNIPROT:O896Z7; UNIPROT:O8OXF8; UNIPROT:O56569; UNIF
PROT:O67915; UNIPROT:O8XU14; UNIPROT:O8Q3D9; UNIPROT:O9MER7; UNIPROT:O9YTT5; UNIPROT:O9
PX80; UNIPROT:O67917; UNIPROT:O9QAQ3; UNIPROT:O99EM0; UNIPROT:O69600; UNIPROT:O8BAP4; UN
C:Genetics:
A:Gene: S

C;Superfamily: hepatitis B virus surface antigen
C;Keywords: surface antigen

Query Match	96.1%	Score 1043;	DB 2;	Length 226;
Best Local Similarity	95.8%	Pred. No. 1,9e-75;		
Matches 181;	Conservative	2;	Mismatches 6;	Indels 0;
				Gaps 0;

QY	DB
1	DSWMTSLNPLGGITVCCGQNSOS
60	PTSNHSPTSCPTCGYRWNCIARRII
60	PLFLILLLCII
33	DSWMTSLNPLGGITVCCGQNSOSPISNHSPTSCPTCGYRWNCIARRII
92	PLFLILLLCII

Qy	Db
61	FLVLALDYQGIPLVPCPLIPGSSSTTSKGCORTCTTPAOSTSMYSSCCCKRPDNGCTCIP1 120
93	FLVLALDYQGMPLVPCPLIPGSSSTTSKGCRTCTTPAOSTSMYSSCCCKRPDNGCTCIP1 152

QY 121 PSSNAFGKYLMEVASARPSWLSLVPFQWFCNLSPTWLSVIMMMKTKGSPSLYSILSPF 180
 :
 Db 153 PSSNAFGKRLMEVASARPSWLSLVPFQWFCVGLSPVWLSVIMMMKTKGSPSLYSILSPF 212

Qy 181 SPLLPFC 189
| | | | |
| | | | |
Db 213 LPPLPFC 221

RESULT 14

surface antigen hepatitis B virus (subtype ayw4)
N/A/ternate names: envelope protein; HBs antigen
N/contains: surface antigen pre-S1 (large envelope protein); surface antigen pre-S2 (mid
C/species: hepatitis B virus, HBV
A/variety: subtype ayw4
C/date: 23-Nov-1994 #sequence_revision 12-May-1995 #text_change 09-Jul-2004
C/accession: S474707 J02071

submitted to the EMBL Data Library, August 1994
A.description: Molecular cloning and sequencing of two complete genomes of polish isolates
A.reference number: S47404

A;Accession: S47407
A;Molecule type: DNA
A;Residues: 1-389 <PLUS>
A;Cross-references: INTPROT:067893; EMBL:Z35716; NID:q522745; PIDD:CAA84788.1; PID:q52274

A: Experimental source: subtype AYV4
R: Norder, H.; Hammar, B.; Lee, S.D.; Bille, K.; Coutouze, A.M.; Mushahwar, I.K.; Magnus,
U. Gen. Virol. 74, 1341-1348, 1993

J: Gen. Virol. 74, 1341-1348, 1993

A;Reference number: JQ2044; MWID:93329383; PMID:8336122
A;Contents: genogroup D
A;Accession: JQ2071

A/Residues: 164-389 <NOB>
A/Experimental source: subtype ayw3, strain 8950/90
C/Genetics:

A, gene: o
A, Introns: 111/3
C, Superfamily: hepatitis B virus surface antigen
C, keywords: surface antigen

P:109-169/Domain:	pre-S2 domain	#status predicted	<SAG>
P:164-189/Product:	surface antigen S (small envelope protein)	#status predicted	<SAG>
P:109-169/Domain:	pre-S2 domain	#status predicted	<PHE2>
P:109-169/Product:	surface antigen pre-S2 (middle envelope protein)	#status predicted	<PHE2>
P:109-169/Domain:	pre-S1 domain	#status predicted	<SAG>
P:109-169/Product:	surface antigen pre-S1 (middle envelope protein)	#status predicted	<SAG>

Query Match	95.9%	Score 1041	DE 2	Length 389
Best Local Similarity	95.8%	Pred. No. 4.2e-76		
Matches 181: Conservative	2	Mismatches	6	Indels 0
		Gaps		0

Qy 1 DSWTSLNPLGATVYCLGONSQSAPTNSPTSCPTCEGYRMCLRRPFIIFLLILCL 60
196 DSWTSLNPLGATVYCLGONSQSAPTNSPTSCPTCEGYRMCLRRPFIIFLLILCL 255

QY 61 FLVLLDLYOQGLPFCPLIPGSSSTSKGQCRCCTTEPAQGSNWSKSCCTKPSDNCICPI 120

Db 256 FLVLLDLYOQGLPFCPLIPGSSSTSVGPCRCCTTIVQSGISMPSCCCTKPSDNCICPI 315

QY 121 PSSWAFGKYLMEWASARFSLVPEVQMFVGLSPTVWLSVIMMMWYMGPSLYSILSPF 180
|||
DB 316 PSSWAFGKFLMEWASARFSLVPEVQMFVGLSPTVWLSVIMMMWYMGPSLYSILSPF 375
|||
QY 181 SPLPIFFC 189
|||
DB 376 LPLPIFFC 384
|||

RESULT 15

JQ1572

major surface antigen - hepatitis B virus (subtype ayw3, strain P3)

C:Species: hepatitis B virus, HBV

A>Note: host Homo sapiens (man)

C:date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 09-Jul-2004

C:Accession: JQ1572

R:Order: H.; Hammas, B.; Loeferahl, S.; Courouce, A.M.; Magnus, L.O.

J. Gen. Virol. 73, 1201-1208, 1992

A>Title: Comparison of the amino acid sequences of nine different serotypes of hepatitis

A:Reference number: JQ1570; PMID:9226879; PMID:1588323

A:Accession: JQ1572

A:Molecule type: DNA

A:Residues: 1-226 <NOR>

A:Cross-references: UNIPROT:O8QXP8; UNIPROT:O56569; UNIPROT:Q67879; UNIPROT:Q998M1; UNIPROT:O8JUN4; UNIPROT:Q9Q3D9; UNIPROT:Q9WHR7; UNIPROT:Q9YTI5; UNIPROT:Q9IF39; UNIPROT:Q9C

FX80; UNIPROT:Q67917; UNIPROT:Q9QAG3; UNIPROT:Q998M0; UNIPROT:Q69600; UNIPROT:Q8BAP4; UN

C:Genetics:

A:Gene: S

C:Superfamily: hepatitis B virus surface antigen

C:Keywords: glycoprotein; surface antigen

F:3/Binding site: carbohydrate (asn) (covalent) #status predicted

Query Match 95.9%; Score 1040; DB 1; Length 226;

Best Local Similarity 95.8%; Pred. No. 3.3e-76;

Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWWTSINFTGTTVCLGNSQSPTSNHSPTSCPTCGYRMWCLRRFLLFLILLCLL 60
|||
DB 33 DSWWTSINFTGTTVCLGNSQSPTSNHSPTSCPTCGYRMWCLRRFLLFLILLCLL 92
|||
QY 61 FLVLDYOGILFVCPILPGSSTTSKQCRCTTPAQGTSMYPSCCCTKPSDGNCTCIP 120
|||
DB 93 FLVLDYOGMLFVCPILPGSSTTSSTGCRCTMTAQTSMYPSCCCTKPSDGNCTCIP 152
|||
QY 121 PSSWAFGKYLMEWASARFSLVPEVQMFVGLSPTVWLSVIMMMWYMGPSLYSILSPF 180
|||
DB 153 PSSWAFGKFLMEWASARFSLVPEVQMFVGLSPTVWLSVIMMMWYMGPSLYSILSPF 212
|||
QY 181 SPLPIFFC 189
|||
DB 213 LPLPIFFC 221
|||

Search completed: July 25, 2005, 11:25:13

Job time : 39 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: July 25, 2005, 11:15:11 / Search time 42 Seconds

(without alignments)
335,921 Million cell updates/sec

Title: US-09-823-077C-7

Perfect score: 1085
Sequence: 1 DSWMTSLNFGTTCVCLGQN.....GPSLSTLSPPSPPLPFC 189Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0
Maximum DB seq length: 200000000Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database: Issued Patents AA.*
1: /cgn2_6/ptodata/1/1aa/5A.COMB.pep.*
2: /cgn2_6/ptodata/1/1aa/5B.COMB.pep.*
3: /cgn2_6/ptodata/1/1aa/6A.COMB.pep.*
4: /cgn2_6/ptodata/1/1aa/6B.COMB.pep.*
5: /cgn2_6/ptodata/1/1aa/PTUS.COMB.pep.*
6: /cgn2_6/ptodata/1/1aa/backfiles.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	1040	95.9	226 4	US-10-104-966-10 Sequence 10, Appl
2	1040	95.9	249 4	US-09-311-784A-16 Sequence 16, Appl
3	1040	95.9	281 1	US-08-105-483-214 Sequence 214, App
4	1040	95.9	281 1	US-08-709-209-214 Sequence 214, App
5	1040	95.9	281 1	US-08-458-101-214 Sequence 214, App
6	1040	95.9	281 4	US-09-247-890-12 Sequence 12, Appl
7	1040	95.9	281 4	US-09-724-969-12 Sequence 12, Appl
8	1040	95.9	281 4	US-09-724-852-12 Sequence 12, Appl
9	1040	95.9	389 1	US-08-105-483-216 Sequence 216, App
10	1040	95.9	389 1	US-08-105-483-219 Sequence 219, App
11	1040	95.9	389 1	US-08-709-209-216 Sequence 216, App
12	1040	95.9	389 1	US-08-709-209-219 Sequence 219, App
13	1040	95.9	389 1	US-08-458-101-216 Sequence 216, App
14	1040	95.9	389 1	US-08-458-101-219 Sequence 219, App
15	1040	95.9	389 3	US-08-486-099-106 Sequence 106, App
16	1040	95.9	389 3	US-08-360-107A-116 Sequence 116, App
17	1040	95.9	389 3	US-08-484-233B-106 Sequence 106, App
18	1040	95.9	389 3	US-08-919-597-106 Sequence 106, App
19	1040	95.9	389 3	US-08-475-668A-106 Sequence 106, App
20	1040	95.9	389 3	US-08-485-551A-106 Sequence 106, App
21	1040	95.9	389 3	US-08-471-913A-106 Sequence 106, App
22	1040	95.9	389 3	US-08-485-264A-106 Sequence 106, App
23	1040	95.9	389 3	US-08-474-349A-106 Sequence 106, App
24	1040	95.9	389 4	US-08-470-896-106 Sequence 106, App
25	1040	95.9	389 4	US-08-485-546A-106 Sequence 106, App
26	1040	95.9	389 4	US-08-487-266A-106 Sequence 106, App
27	1040	95.9	397 5	PCT-US96-10602-6 Sequence 6, Appl

28	1033	95.2	226 5	PCT-US96-10602-14 Sequence 14, Appl
29	1007	92.8	225 6	5436139-4 Patent No. 5436139
30	1007	92.8	225 6	5436139-4 Patent No. 5436139
31	1007	92.8	226 6	5196194-21 Patent No. 5196194
32	1007	92.8	226 6	5436139-5 Patent No. 5436139
33	1007	92.8	226 6	5196194-21 Patent No. 5196194
34	1007	92.8	226 6	5436139-5 Patent No. 5436139
35	1007	92.8	281 4	US-09-721-480-3 Sequence 3, Appl
36	1007	92.8	390 4	US-09-721-480-5 Sequence 5, Appl
37	1007	92.8	531 4	US-09-721-480-7 Sequence 7, Appl
38	1004	92.5	387 4	US-09-350-841A-1592 Sequence 1592, App
39	1004	92.5	423 2	US-08-760-797A-1 Sequence 1, Appl
40	1004	92.5	424 3	US-08-760-797A-3 Sequence 3, Appl
41	1004	92.5	424 3	US-08-932-929B-1 Sequence 1, Appl
42	1004	92.5	424 3	US-08-932-929B-3 Sequence 3, Appl
43	995.5	91.8	395 6	5196194-18 Patent No. 5196194
44	995.5	91.8	395 6	5196194-18 Patent No. 5196194
45	992	91.4	226 1	US-08-378-011A-3 Sequence 3, Appl

ALIGNMENTS

```
RESULT 1
US-10-104-966-10
Sequence 10, Application US/10104966
Patent No. 6680059
GENERAL INFORMATION:
APPLICANT: Marti Salberg
TITLE OF INVENTION: VACCINES CONTAINING RIBAVIRIN AND
FILE REFERENCE: TRIPEP.23AUSC1
CURRENT APPLICATION NUMBER: US/10/104,966
CURRENT FILING DATE: 2002-03-22
PRIOR APPLICATION NUMBER: 09/705,547
PRIOR FILING DATE: 2000-11-03
PRIOR APPLICATION NUMBER: 60/229,175
PRIOR FILING DATE: 2000-08-29
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 10
LENGTH: 226
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURES:
OTHER INFORMATION: Hepatitis B virus S antigen (HBeAg) sequence
US-10-104-966-10
Query Match 95.9%; Score 1040; DB 4; Length 226;
Best Local Similarity 95.8%; Pred. No. 7.7e-89;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
QY 1 DSWMTSLNFGTTCVCLGQNSQSTSNHSPSCPTCPGRMCLRRPILFLILLCL 60
DB 33 DSWMTSLNFGTTCVCLGQNSQSTSNHSPSCPTCPGRMCLRRPILFLILLCL 92
QY 61 FLVLLDYOGILPYCPILPSSSTSKGCRCTCPAOGTSMYPSGCCCKPSDGNCTCPI 120
DB 93 FLVLLDYOGILPYCPILPSSSTSKGCRCTCPAOGTSMYPSGCCCKPSDGNCTCPI 152
QY 121 PSSNAFGKLYEMNASARFWSLSLVPPVQWFGSLPTVWLSVIMWMYGBSLYSLSPF 180
DB 153 PSSNAFGKLYEMNASARFWSLSLVPPVQWFGSLPTVWLSVIMWMYGBSLYSLSPF 212
QY 181 SPLPIRPF 189
DB 213 SPLPIRPF 221
RESULT 2
US-09-311-784A-16
Sequence 16, Application US/09311784A
```

Patent No. 6534482
GENERAL INFORMATION:
APPLICANT: Fikes, John D.
APPLICANT: Hermanson, Gary G.
APPLICANT: Sette, Alessandro
APPLICANT: Ishioka, Glenn Y.
APPLICANT: Livingston, Brian
APPLICANT: Chesnut, Robert W.
APPLICANT: Epiimmune Inc.
TITLE OF INVENTION: Expression Vectors for Stimulating an
TITLE OF INVENTION: Immune Response and Methods of Using the Same
FILE REFERENCE: 39963-20022.01
CURRENT APPLICATION NUMBER: US/09/311.784A
CURRENT FILING DATE: 1999-05-13
PRIOR APPLICATION NUMBER: US 60/085,751
PRIOR FILING DATE: 1998-05-15
NUMBER OF SEQ ID NOS: 463
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 16
LENGTH: 249
TYPE: PRF
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PADRE-HBV-s
US-09-311-784A-16

Query Match 95.9%; Score 1040; DB 4; Length 249;
Best Local Similarity 95.8%; Pred. No. 8.6e-89;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNFGGTTVCLGQNSQSPSTNSHPTSCPTCPGRRMCLRRFIIFLLILCL 60
DB 56 DSWMTSLNFGGTTVCLGQNSQSPSTNSHPTSCPTCPGRRMCLRRFIIFLLILCL 115
QY 61 FLVLVDYQGLVPCPLIPSSSTTSKGQCRCTCTTCTPAQGTSMYPSCCCTKPSDNGCTCIP 120
DB 116 FLVLVDYQGLVPCPLIPSSSTTSKGQCRCTCTTCTPAQGTSMYPSCCCTKPSDNGCTCIP 175
QY 121 PSSWATGKIYMEWASAFWSLVLVPVQWFGVLSPTVMTSVTMMWYMGPSLYSILSPF 180
DB 176 PSSWATGKIYMEWASAFWSLVLVPVQWFGVLSPTVMTSVTMMWYMGPSLYSILSPF 235
QY 181 SPLPIFFC 189
DB 236 SPLPIFFC 244

RESULT 3
US-08-105-483-214
Sequence 214, Application US/08105483
Patent No. 5494807
GENERAL INFORMATION:
APPLICANT: Paolletti, Enzo
TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
TITLE OF INVENTION: STRAIN
NUMBER OF SEQUENCES: 462
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
ADDRESSER: c/o William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/105,483
FILING DATE: 12-AUG-1993
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/847,951
FILING DATE: 06-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2400
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 214:
SEQUENCE CHARACTERISTICS:
LENGTH: 281 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-105-483-214

Query Match 95.9%; Score 1040; DB 1; Length 281;
Best Local Similarity 95.8%; Pred. No. 9.8e-89;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNFGGTTVCLGQNSQSPSTNSHPTSCPTCPGRRMCLRRFIIFLLILCL 60
DB 88 DSWMTSLNFGGTTVCLGQNSQSPSTNSHPTSCPTCPGRRMCLRRFIIFLLILCL 147
QY 61 FLVLVDYQGLVPCPLIPSSSTTSKGQCRCTCTTCTPAQGTSMYPSCCCTKPSDNGCTCIP 120
DB 148 FLVLVDYQGLVPCPLIPSSSTTSKGQCRCTCTTCTPAQGTSMYPSCCCTKPSDNGCTCIP 207
QY 121 PSSWATGKIYMEWASAFWSLVLVPVQWFGVLSPTVMTSVTMMWYMGPSLYSILSPF 180
DB 208 PSSWATGKIYMEWASAFWSLVLVPVQWFGVLSPTVMTSVTMMWYMGPSLYSILSPF 267
QY 181 SPLPIFFC 189
DB 268 SPLPIFFC 276

RESULT 4
US-08-709-209-214
Sequence 214, Application US/08709209
Patent No. 5762938
GENERAL INFORMATION:
APPLICANT: Paolletti, Enzo
TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
TITLE OF INVENTION: STRAIN
NUMBER OF SEQUENCES: 462
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
ADDRESSER: c/o William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/709,209
FILING DATE: 21-AUG-1996
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/105,483
FILING DATE: 12-AUG-1993
APPLICATION NUMBER: US 07/847,951
FILING DATE: 06-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506

REFERENCE/DOCKET NUMBER: 454310-2400
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 214:
SEQUENCE CHARACTERISTICS:
LENGTH: 281 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-709-209-214

Query Match 95.9%; Score 1040; DB 1; Length 281;
Best Local Similarity 95.8%; Pred. No. 9.8e-89;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLGTTVCAGNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLFIILLCI 60
DB 88 DSWMTSLNPLGTTVCAGNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLFIILLCI 147
QY 61 FLVLVDYQGLPVCPLIPGSSSTTSKGQCRCTTTPAOSTMYPSCCCTKPSDGNCTCPI 120
DB 148 FLVLVDYQGLPVCPLIPGSSSTTSKGQCRCTTTPAOSTMYPSCCCTKPSDGNCTCPI 207
QY 121 PSSWAFKRTIMENASARFWSLSLVPVQWFGVLSPTVWLSVIMMMYMGPSLYSLISPF 180
DB 208 PSSWAFKRTIMENASARFWSLSLVPVQWFGVLSPTVWLSVIMMMYMGPSLYSLISPF 267
QY 181 SPLPIFFC 189
DB 268 LPLPIFFC 276

RESULT 5

US-08-458-101-214
Sequence 214, Application US/08458101
Patent No. 5766599
GENERAL INFORMATION:
APPLICANT: Paolletti, Enzo
APPLICANT: Perkins, Marton E.
APPLICANT: Taylor, Jill
APPLICANT: Tartaglia, James
APPLICANT: No. 5766599, Elizabeth K.
APPLICANT: Riviere, Michel
APPLICANT: de Taisne, Charles
APPLICANT: Limbach, Keith J.
APPLICANT: Johnson, Gerard P.
APPLICANT: Pincus, Steven E.
APPLICANT: Cox, William I.
APPLICANT: Audonnet, Jean-Christophe Francis
APPLICANT: Gettis, Russell Robert
TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
TITLE OF INVENTION: STAIN
NUMBER OF SEQUENCES: 467
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
ADDRESSEE: c/o William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/458,101
FILING DATE: 01-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.

REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2740
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 214:
SEQUENCE CHARACTERISTICS:
LENGTH: 281 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-458-101-214

Query Match 95.9%; Score 1040; DB 1; Length 281;
Best Local Similarity 95.8%; Pred. No. 9.8e-89;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLGTTVCAGNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLFIILLCI 60
DB 88 DSWMTSLNPLGTTVCAGNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLFIILLCI 147
QY 61 FLVLVDYQGLPVCPLIPGSSSTTSKGQCRCTTTPAOSTMYPSCCCTKPSDGNCTCPI 120
DB 148 FLVLVDYQGLPVCPLIPGSSSTTSKGQCRCTTTPAOSTMYPSCCCTKPSDGNCTCPI 207
QY 121 PSSWAFKRTIMENASARFWSLSLVPVQWFGVLSPTVWLSVIMMMYMGPSLYSLISPF 180
DB 208 PSSWAFKRTIMENASARFWSLSLVPVQWFGVLSPTVWLSVIMMMYMGPSLYSLISPF 267
QY 181 SPLPIFFC 189
DB 268 LPLPIFFC 276

RESULT 6

US-09-247-890-12
Sequence 12, Application US/09247890
Patent No. 654101
GENERAL INFORMATION:
APPLICANT: Punnonen, Juha
APPLICANT: Baas, Steven H.
APPLICANT: Whalen, Robert Gerald
APPLICANT: Howard, Russell
APPLICANT: Stemmer, William P.C.
APPLICANT: Maxygen, Inc.
TITLE OF INVENTION: Antigen Library Immunization
FILE REFERENCE: 018097-028710US
CURRENT APPLICATION NUMBER: US/09/247,890
CURRENT FILING DATE: 1999-02-10
EARLIER FILING DATE: 1998-02-11
EARLIER APPLICATION NUMBER: US 60/105,509
EARLIER FILING DATE: 1998-10-23
NUMBER OF SEQ ID NOS: 25
SOFTWARE: Patent Ver. 2.0
SEQ ID NO 12
LENGTH: 281
TYPE: PRT
ORGANISM: Hepatitis B virus
US-09-247-890-12

Query Match 95.9%; Score 1040; DB 4; Length 281;
Best Local Similarity 95.8%; Pred. No. 9.8e-89;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLGTTVCAGNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLFIILLCI 60
DB 88 DSWMTSLNPLGTTVCAGNSQSPSTNSHSPSCPTCGYRMCLRRPIIFLFIILLCI 147
QY 61 FLVLVDYQGLPVCPLIPGSSSTTSKGQCRCTTTPAOSTMYPSCCCTKPSDGNCTCPI 120
DB 148 FLVLVDYQGLPVCPLIPGSSSTTSKGQCRCTTTPAOSTMYPSCCCTKPSDGNCTCPI 207

Qy	121	PSSNAAGKTLMEASASRPSMTLSLVPFVQMFGSLSPVTWLSVIWMWYMGSLYSISPF	189
	:		
D _b	208	PSSMAFGKFLMEMASASRPSMTLSLVPFVQMFGSLSPVTWLSVIWMWYMGSLYSISPF	267
Qy	181	SPLLPFFC	189
	:		
D _b	268	LPLPPIFFC	276

RESULT 7
US-09-724-969-12
; Sequence 12, Application US/09724965

ORGANISM: Hepatitis B virus
US-09-724-969-12

RESULT 8
US-09-724-852-12
Sequence 12, Application US/09724852
Patent No. 6576757
GENERAL INFORMATION:
APPLICANT: Pannonen, Juha
APPLICANT: Baas, Steven H.
APPLICANT: Whalen, Robert Gerald
APPLICANT: Howard, Russell
APPLICANT: Stemmer, Willem P. C.
APPLICANT: Maxygen, Inc.
TITLE OF INVENTION: AntiYgen Library Immunizations
FILE REFERENCE: 018097-028710US
CURRENT APPLICATION NUMBER: US/09/724,852
CURRENT FILING DATE: 2000-11-28
PRIOR APPLICATION NUMBER: US/09/247,890

```

1 PRIOR FILING DATE: 1999-02-10 APPLICATION NUMBER: US 60/074,299
2 PRIOR APPLICATION NUMBER: EARLIER FILING DATE: 1998-02-11
3 PRIOR FILING DATE: EARLIER FILING DATE: 1998-02-11
4 PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/105,506
5 PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-23
6 NUMBER OF SEQ ID NOS: 25
7 SOFTWARE: Patentin Ver. 2.0
8 SEQ ID NO 12
9 LENGTH: 281
10 TYPE: PRF
11 ORGANISM: Hepatitis B virus
12 US-09-724-852-12

```

Query Match	95.9%;	Score 1040;	DB 4;	Length 281;
Best Local Similarity	95.8%;	Pred. No. 9.8e-89;		
Matches 181; Conservative	2;	Mismatches 6;	Indels 0;	Gaps 0

RESULT 9
 US-08-105-483-216
 Sequence 216, Application US/08105483
 Patent No. 5494807
 GENERAL INFORMATION:
 APPLICANT: Paolucci, Enzo
 TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
 TITLE OF INVENTION: STRAIN
 NUMBER OF SEQUENCES: 462
 CORRESPONDENCE ADDRESS:
 ADDRESSES: Curtiss, Morris & Safford
 ADDRESSES: c/o William S. Frommer
 STREET: 530 Fifth Avenue
 CITY: New York
 STATE: NY
 COUNTRY: USA
 ZIP: 10036
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/105,483
 FILING DATE: 12-AUG-1993
 CLASSIFICATION: 424
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/847,951
 FILING DATE: 06-MAR-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Frommer, William S.
 REGISTRATION NUMBER: 25,506
 REFERENCE/DOCKET NUMBER: 454310-2400
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 840-3333
 TELEFAX: (212) 840-0712
 INFORMATION FOR SEQ ID NO: 216:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 389 amino acids

TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-105-483-216

Query Match 95.9%; Score 1040; DB 1; Length 389;
Best Local Similarity 95.8%; Pred. No. 1.4e-88;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLGTTTCGONSQSPSTNSPTSCPTCGYRMCLRRPIIFLLICLI 60
DB DSWMTSLNPLGTTTCGONSQSPSTNSPTSCPTCGYRMCLRRPIIFLLICLI 255
QY 61 FLVVLADYQGLPVCPLIPGSSSTTSKQCRCTTTPAOGTSMYPSCCCTKPSDGNCTCIP 120
DB FLVVLADYQGLPVCPLIPGSSSTTSKQCRCTTTPAOGTSMYPSCCCTKPSDGNCTCIP 315
QY 121 PSSWAFGKFLWEMASARFWSLVLVPVQWFGVLSPTVWLSVIMWMMYWGPSLYSIISPF 180
DB PSSWAFGKFLWEMASARFWSLVLVPVQWFGVLSPTVWLSVIMWMMYWGPSLYSIISPF 375
QY 181 SPLPIFFC 189
DB SPLPIFFC 384

RESULT 10

US-08-105-483-219
Sequence 219, Application US/08105483
Patent No. 5494807

GENERAL INFORMATION:

APPLICANT: Paoletti, Enzo

TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE

TITLE OF INVENTION: STRAIN

NUMBER OF SEQUENCES: 462

CORRESPONDENCE ADDRESS:

ADDRESSEE: Curtis, Morris & Safford

ADDRESS: c/o William S. Frommer

STREET: 530 Fifth Avenue

CITY: New York

STATE: NY

COUNTRY: USA

ZIP: 10036

COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/105,483

FILING DATE: 12-AUG-1993

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/847,951

FILING DATE: 06-MAR-1992

ATTORNEY/AGENT INFORMATION:

NAME: Frommer, William S.

REGISTRATION NUMBER: 25,506

REFERENCE/DOCKET NUMBER: 454310-2400

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 840-3333

TELEFAX: (212) 840-0712

INFORMATION FOR SEQ ID NO: 219:

SEQUENCE CHARACTERISTICS:

LENGTH: 389 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-105-483-219

Query Match 95.9%; Score 1040; DB 1; Length 389;
Best Local Similarity 95.8%; Pred. No. 1.4e-88;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLGTTTCGONSQSPSTNSPTSCPTCGYRMCLRRPIIFLLICLI 60
DB DSWMTSLNPLGTTTCGONSQSPSTNSPTSCPTCGYRMCLRRPIIFLLICLI 255
QY 61 FLVVLADYQGLPVCPLIPGSSSTTSKQCRCTTTPAOGTSMYPSCCCTKPSDGNCTCIP 120
DB FLVVLADYQGLPVCPLIPGSSSTTSKQCRCTTTPAOGTSMYPSCCCTKPSDGNCTCIP 315
QY 121 PSSWAFGKFLWEMASARFWSLVLVPVQWFGVLSPTVWLSVIMWMMYWGPSLYSIISPF 180
DB PSSWAFGKFLWEMASARFWSLVLVPVQWFGVLSPTVWLSVIMWMMYWGPSLYSIISPF 375
QY 181 SPLPIFFC 189
DB SPLPIFFC 384

RESULT 11

US-08-709-209-216
Sequence 216, Application US/08709209
Patent No. 5762938

GENERAL INFORMATION:

APPLICANT: Paoletti, Enzo

TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE

TITLE OF INVENTION: STRAIN

NUMBER OF SEQUENCES: 462

CORRESPONDENCE ADDRESS:

ADDRESSEE: Curtis, Morris & Safford

ADDRESS: c/o William S. Frommer

STREET: 530 Fifth Avenue

CITY: New York

STATE: NY

COUNTRY: USA

ZIP: 10036

COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/709,209

FILING DATE: 21-AUG-1996

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/105,483

FILING DATE: 12-AUG-1993

APPLICATION NUMBER: US 07/847,951

FILING DATE: 06-MAR-1992

ATTORNEY/AGENT INFORMATION:

NAME: Frommer, William S.

REGISTRATION NUMBER: 25,506

REFERENCE/DOCKET NUMBER: 454310-2400

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 840-3333

TELEFAX: (212) 840-0712

INFORMATION FOR SEQ ID NO: 216:

SEQUENCE CHARACTERISTICS:

LENGTH: 389 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-709-209-216

Query Match 95.9%; Score 1040; DB 1; Length 389;
Best Local Similarity 95.8%; Pred. No. 1.4e-88;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNPLGTTTCGONSQSPSTNSPTSCPTCGYRMCLRRPIIFLLICLI 60
DB DSWMTSLNPLGTTTCGONSQSPSTNSPTSCPTCGYRMCLRRPIIFLLICLI 255
QY 61 FLVVLADYQGLPVCPLIPGSSSTTSKQCRCTTTPAOGTSMYPSCCCTKPSDGNCTCIP 120

Db 256 FLVLLVDYQGLPVCLIPGSSSTTSGPCRTCTMTTACGISMYSGCCCTKPSDNCCTCIP 315
QY 121 PSSMAFGKLTWEMASARFMSLSLVPFVQMFVGLSPTVWLSVIMMMYMGPSLSYLSLSP 180
Db 316 PSSMAFGKLTWEMASARFMSLSLVPFVQMFVGLSPTVWLSVIMMMYMGPSLSYLSLSP 375
QY 181 SPLPIFFC 189
Db 376 LPLPIFFC 384

RESULT 12

US-08-709-209-219
Sequence 219, Application US/08709209
Patent No. 5762938
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
NUMBER OF SEQUENCES: 462
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/709,209
FILING DATE: 21-AUG-1996
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/105,483
FILING DATE: 12-AUG-1993
APPLICATION NUMBER: US 07/847,951
FILING DATE: 06-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2400
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 219:
SEQUENCE CHARACTERISTICS:
LENGTH: 389 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-709-209-219

Query Match 95.9%; Score 1040; DB 1; Length 389;
Best Local Similarity 95.8%; Pred. No. 1.4e-88;

Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTVCLGQNSQPTSNHSPSCPTCPGYRMCLRRFTIFLFIILLCL 60
Db 196 DSWMTSLNFIAGTTVCLGQNSQPTSNHSPSCPTCPGYRMCLRRFTIFLFIILLCL 255
QY 61 FLVLLVDYQGLPVCLIPGSSSTTSGPCRTCTMTTACGISMYSGCCCTKPSDNCCTCIP 120
Db 256 FLVLLVDYQGLPVCLIPGSSSTTSGPCRTCTMTTACGISMYSGCCCTKPSDNCCTCIP 315
QY 121 PSSMAFGKLTWEMASARFMSLSLVPFVQMFVGLSPTVWLSVIMMMYMGPSLSYLSLSP 180
Db 316 PSSMAFGKLTWEMASARFMSLSLVPFVQMFVGLSPTVWLSVIMMMYMGPSLSYLSLSP 375

QY 181 SPLPIFFC 189
Db 376 LPLPIFFC 384

RESULT 13

US-08-458-101-216
Sequence 216, Application US/08458101
Patent No. 5765599
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Perkus, Marlon B.
APPLICANT: Taylor, Jill
APPLICANT: Tartaglia, James
APPLICANT: No. 5765599con, Elizabeth K.
APPLICANT: Riviere, Michel
APPLICANT: de Taisne, Charles
APPLICANT: Limbach, Keith J.
APPLICANT: Johnson, Gerard P.
APPLICANT: Placus, Steven B.
APPLICANT: Cox, William I.
APPLICANT: Audomert, Jean-Christophe Francis
APPLICANT: Gettig, Russell Robert
TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
NUMBER OF SEQUENCES: 467
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/458,101
FILING DATE: 01-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2740
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 216:
SEQUENCE CHARACTERISTICS:
LENGTH: 389 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-458-101-216

Query Match 95.9%; Score 1040; DB 1; Length 389;
Best Local Similarity 95.8%; Pred. No. 1.4e-88;

Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DSWMTSLNFIAGTTVCLGQNSQPTSNHSPSCPTCPGYRMCLRRFTIFLFIILLCL 60
Db 196 DSWMTSLNFIAGTTVCLGQNSQPTSNHSPSCPTCPGYRMCLRRFTIFLFIILLCL 255
QY 61 FLVLLVDYQGLPVCLIPGSSSTTSGPCRTCTMTTACGISMYSGCCCTKPSDNCCTCIP 120
Db 256 FLVLLVDYQGLPVCLIPGSSSTTSGPCRTCTMTTACGISMYSGCCCTKPSDNCCTCIP 315
QY 121 PSSMAFGKLTWEMASARFMSLSLVPFVQMFVGLSPTVWLSVIMMMYMGPSLSYLSLSP 180

316 PSSNAFGKXLMENASAFSWSLILVFPVQVGLSPTVWLSVIMMMWYWGSLYSILSPF 375
 181 SPLLPFPFC 189
 376 LPLLPFPFC 384

RESULT 14

US-08-458-101-219
 Sequence 219, Application US/08458101

Patent No. 5766599

GENERAL INFORMATION:

APPLICANT: Paolletti, Enzo

APPLICANT: Perkins, Marion B.

APPLICANT: Taylor, Jill

APPLICANT: Tartaglia, James

APPLICANT: No. 5766599, Elizabeth K.

APPLICANT: Riviere, Michel

APPLICANT: de Talsne, Charles

APPLICANT: Lambach, Keith J.

APPLICANT: Johnson, Gerard P.

APPLICANT: Pincus, Steven E.

APPLICANT: Cox, William I.

APPLICANT: Audonnet, Jean-Christophe Francis

TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE

TITLE OF INVENTION: STRAIN

NUMBER OF SEQUENCES: 467

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Curtis, Morris & Safford

STREET: 530 Fifth Avenue

CITY: New York

STATE: NY

COUNTRY: USA

ZIP: 10036

COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/458,101

FILING DATE: 01-JUN-1995

CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:

NAME: Frommer, William S.

REGISTRATION NUMBER: 25,506

REFERENCE/DOCKET NUMBER: 454310-2740

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 840-3333

TELEFAX: (212) 840-0712

INFORMATION FOR SEQ ID NO: 219:

SEQUENCE CHARACTERISTICS:

LENGTH: 389 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-458-101-219

Query Match 95.9%, Score 1040, DB 1, Length 389,
 Best Local Similarity 95.8%, Pred. No. 1.4e-88,
 Matches 181, Conservative 2, Mismatches 6, Indels 0, Gaps 0,

316 PSSNAFGKXLMENASAFSWSLILVFPVQVGLSPTVWLSVIMMMWYWGSLYSILSPF 375
 181 SPLLPFPFC 189
 376 LPLLPFPFC 384

RESULT 15

US-08-486-099-106
 Sequence 106, Application US/08486099

Patent No. 6013263

GENERAL INFORMATION:

APPLICANT: Bolognesi, Paul P.

APPLICANT: Matthews, Thomas J.

APPLICANT: Wild, Carl T.

APPLICANT: Barney, Shawn O.

APPLICANT: Lambert, Dennis M.

APPLICANT: Peteway, Stephen R.

APPLICANT: Langlois, Alphonse J.

TITLE OF INVENTION: COMPOSITIONS FOR INHIBITION OF

TITLE OF INVENTION: MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HEPATITIS

NUMBER OF SEQUENCES: 209

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Pennie & Edmonds

STREET: 1155 Avenue of the Americas

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10036-2711

COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/486,099

FILING DATE: 07-JUN-1995

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Coruzzi, Laura A.

REGISTRATION NUMBER: 30,742

REFERENCE/DOCKET NUMBER: 7872-031

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 790-9090

TELEFAX: (212) 869-9741/8864

INFORMATION FOR SEQ ID NO: 106:

SEQUENCE CHARACTERISTICS:

LENGTH: 389 amino acids

TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: unknown

MOLECULAR TYPE: protein

US-08-486-099-106

Query Match 95.9%, Score 1040, DB 3, Length 389,
 Best Local Similarity 95.8%, Pred. No. 1.4e-88,
 Matches 181, Conservative 2, Mismatches 6, Indels 0, Gaps 0,

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using BW model

Run on: July 25, 2005, 11:24:37 / Search time 156 Seconds
(without alignments)
471.279 Million cell updates/sec

Title: US-09-823-077C-7
Perfect score: 1085
Sequence: 1 DSWMTSLNPLGCTVCLGQN.....GPSLYSLSPSPPLPFFFC 189

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1741741 seqs, 388992284 residues

Total number of hits satisfying chosen parameters: 1741741

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/PCTI_NEM_PUB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEM_PUB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEM_PUB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEM_PUB.pep:*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEM_PUB.pep:*
13: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep:*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep:*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep:*
18: /cgn2_6/ptodata/1/pubpaa/US10F_NEM_PUB.pep:*
19: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*
20: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep:*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEM_PUB.pep:*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1046	96.4	226	14	US-10-169-668-5
2	1046	96.4	389	14	US-10-169-668-6
3	1043	96.1	226	18	US-10-911-648-36
4	1040	95.9	226	9	US-09-929-955-10
5	1040	95.9	226	13	US-10-104-966-10
6	1040	95.9	226	15	US-10-719-619-10
7	1040	95.9	226	16	US-10-817-581-10
8	1040	95.9	227	16	US-10-472-724-17
9	1040	95.9	249	15	US-10-371-525-16
10	1040	95.9	249	15	US-10-371-069-16
11	1040	95.9	249	15	US-10-371-645-16

12	1040	95.9	249	15	US-10-371-260-16	Sequence 16, Appl
13	1040	95.9	281	9	US-09-247-890-12	Sequence 12, Appl
14	1040	95.9	281	15	US-10-383-117-12	Sequence 12, Appl
15	1040	95.9	334	16	US-10-472-724-10	Sequence 10, Appl
16	1040	95.9	389	15	US-10-267-682-106	Sequence 106, App
17	1040	95.9	389	15	US-10-267-682-106	Sequence 106, App
18	1040	95.9	397	9	US-09-812-862-6	Sequence 6, Appl
19	1033	95.2	226	9	US-09-812-862-14	Sequence 14, Appl
20	1033	95.2	389	9	US-09-812-877-2	Sequence 2, Appl
21	1033	95.2	389	16	US-10-847-493-2	Sequence 2, Appl
22	1032	95.1	229	9	US-09-821-877-8	Sequence 8, Appl
23	1032	95.1	229	16	US-10-847-493-8	Sequence 8, Appl
24	1026	94.6	305	18	US-10-911-648-30	Sequence 30, Appl
25	1007	92.8	226	17	US-10-838-834-14	Sequence 14, Appl
26	1007	92.8	281	18	US-10-715-665-3	Sequence 3, Appl
27	1007	92.8	390	18	US-10-715-665-5	Sequence 5, Appl
28	1007	92.8	454	17	US-10-912-869-38	Sequence 38, Appl
29	1007	92.8	531	18	US-10-715-665-7	Sequence 7, Appl
30	1007	92.8	678	15	US-10-365-620-29	Sequence 29, Appl
31	1007	92.8	678	15	US-10-365-620-32	Sequence 32, Appl
32	1007	92.8	678	17	US-10-912-969-36	Sequence 36, Appl
33	1007	92.8	678	17	US-10-912-969-36	Sequence 36, Appl
34	991	91.3	226	15	US-10-335-774-2	Sequence 2, Appl
35	991	91.3	226	15	US-10-335-774-40	Sequence 40, Appl
36	988	91.1	400	15	US-10-411-026-46	Sequence 46, Appl
37	988	91.1	400	15	US-10-411-026-46	Sequence 46, Appl
38	988	91.1	400	15	US-10-411-026-46	Sequence 46, Appl
39	988	91.1	400	15	US-10-411-026-46	Sequence 46, Appl
40	988	91.1	400	16	US-10-410-930-46	Sequence 46, Appl
41	988	91.1	400	16	US-10-410-930-46	Sequence 46, Appl
42	988	91.1	400	16	US-10-410-930-46	Sequence 46, Appl
43	988	91.1	400	16	US-10-410-930-46	Sequence 46, Appl
44	988	91.1	400	16	US-10-287-994-46	Sequence 46, Appl
45	988	91.1	400	17	US-10-410-913-46	Sequence 46, Appl
					US-10-410-980-46	Sequence 46, Appl

ALIGNMENTS

RESULT 1

US-10-169-668-5
; Sequence 5, Application US/10169668
; Publication No. US20030129202A1
; GENERAL INFORMATION:
; APPLICANT: BIONEERIEUX
; TITLE OF INVENTION: MUTATED HEPATITIS B VIRUS, ITS NUCLEIC AND PROTEIN
; FILE REFERENCE: IFB 99 INS HEV
; CURRENT FILING DATE: 2002-07-08
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 5
; LENGTH: 226
; TYPE: PRT
; ORGANISM: mutated hepatitis B virus mHBV
US-10-169-668-5

Query Match 96.4% Score 1046; DB 14; Length 226;
Best Local Similarity 95.8%; Pred. No. 1.9e-82;
Matches 181; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY	1	DSWMTSLNPLGCTVCLGQNSQSPSTNSPTSCPTCGYMMCLRRPILFLILLCLLI	60
DB	33	DSWMTSLNPLGCTVCLGQNSQSPSTNSPTSCPTCGYMMCLRRPILFLILLCLLI	92
QY	61	FLVTLVDVQGLPLPCPLPGSSTTSKQCRCTTTPAGTSMYBSCCCCKBBDGNTCIP	120
DB	93	FLVTLVDVQGLPLPCPLPGSSTTSKQCRCTTTPAGTSMYBSCCCCKBBDGNTCIP	152
QY	121	PSNAFGKYLKEMASRPSWLSLVPFQWFGVGLPTWLSVIMWMWTWGSLSLSPF	180

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: July 25, 2005, 11:24:37 ; Search time 156 Seconds

(without alignments)
471.279 Million cell updates/sec

Title: US-09-823-077C-7

Perfect score: 1085
Sequence: 1 DSMWTSINFLGAGTTVCAGQN.....GPSLXSLSPSPPLPIFC 189

Scoring table:
BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1741741 seqs, 388992284 residues

Total number of hits satisfying chosen parameters: 1741741

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

Published Applications AA:*

- 1: /cgn2_6/ptodata/1/pubppaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/1/pubppaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/1/pubppaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/1/pubppaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/1/pubppaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/1/pubppaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/ptodata/1/pubppaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/1/pubppaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/ptodata/1/pubppaa/US09_PUBCOMB.pep.*
- 10: /cgn2_6/ptodata/1/pubppaa/US09B_PUBCOMB.pep.*
- 11: /cgn2_6/ptodata/1/pubppaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/ptodata/1/pubppaa/US09A_PUBCOMB.pep.*
- 13: /cgn2_6/ptodata/1/pubppaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/ptodata/1/pubppaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/ptodata/1/pubppaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/ptodata/1/pubppaa/US10D_PUBCOMB.pep.*
- 17: /cgn2_6/ptodata/1/pubppaa/US10E_PUBCOMB.pep.*
- 18: /cgn2_6/ptodata/1/pubppaa/US10F_PUBCOMB.pep.*
- 19: /cgn2_6/ptodata/1/pubppaa/US11A_PUBCOMB.pep.*
- 20: /cgn2_6/ptodata/1/pubppaa/US11A_NEW_PUB.pep.*
- 21: /cgn2_6/ptodata/1/pubppaa/US60_NEW_PUB.pep.*
- 22: /cgn2_6/ptodata/1/pubppaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1046	96.4	226 14 US-10-169-668-5	Sequence 5, Appl
2	1046	96.4	389 14 US-10-169-668-6	Sequence 6, Appl
3	1043	96.1	226 18 US-10-911-4648-36	Sequence 36, Appl
4	1040	95.9	226 9 US-09-929-955-10	Sequence 10, Appl
5	1040	95.9	226 13 US-10-104-966-10	Sequence 10, Appl
6	1040	95.9	226 15 US-10-719-619-10	Sequence 10, Appl
7	1040	95.9	226 16 US-10-817-591-10	Sequence 10, Appl
8	1040	95.9	227 16 US-10-472-724-27	Sequence 27, Appl
9	1040	95.9	249 15 US-10-371-525-16	Sequence 16, Appl
10	1040	95.9	249 15 US-10-371-069-16	Sequence 16, Appl
11	1040	95.9	249 15 US-10-371-645-16	Sequence 16, Appl

12	1040	95.9	249 15 US-10-371-260-16	Sequence 16, Appl
13	1040	95.9	281 9 US-09-247-890-12	Sequence 12, Appl
14	1040	95.9	281 15 US-10-363-317-12	Sequence 12, Appl
15	1040	95.9	334 16 US-10-472-724-10	Sequence 10, Appl
16	1040	95.9	389 15 US-10-267-682-106	Sequence 106, App
17	1040	95.9	389 15 US-10-267-748-106	Sequence 106, App
18	1040	95.9	397 9 US-09-812-862-6	Sequence 6, Appl
19	1033	95.2	226 9 US-09-812-862-14	Sequence 14, Appl
20	1033	95.2	389 9 US-09-821-877-2	Sequence 2, Appl
21	1033	95.2	389 16 US-10-847-493-2	Sequence 2, Appl
22	1032	95.1	229 9 US-09-821-877-8	Sequence 8, Appl
23	1032	95.1	229 16 US-10-847-493-8	Sequence 8, Appl
24	1026	94.6	305 18 US-10-911-4648-30	Sequence 30, Appl
25	1007	92.8	226 17 US-10-838-834-14	Sequence 14, Appl
26	1007	92.8	381 18 US-10-715-665-3	Sequence 3, Appl
27	1007	92.8	390 18 US-10-715-665-5	Sequence 3, Appl
28	1007	92.8	454 17 US-10-912-969-38	Sequence 38, Appl
29	1007	92.8	531 16 US-10-715-665-7	Sequence 7, Appl
30	1007	92.8	678 15 US-10-365-620-29	Sequence 29, Appl
31	1007	92.8	678 15 US-10-365-620-32	Sequence 32, Appl
32	1007	92.8	678 17 US-10-912-969-36	Sequence 36, Appl
33	1007	92.8	678 17 US-10-913-171-29	Sequence 29, Appl
34	991	91.3	226 15 US-10-335-774-2	Sequence 2, Appl
35	991	91.3	226 15 US-10-335-774-40	Sequence 40, Appl
36	988	91.1	400 15 US-10-411-037-46	Sequence 46, Appl
37	988	91.1	400 15 US-10-411-026-46	Sequence 46, Appl
38	988	91.1	400 15 US-10-411-049-46	Sequence 46, Appl
39	988	91.1	400 15 US-10-411-049-46	Sequence 46, Appl
40	988	91.1	400 16 US-10-410-930-46	Sequence 46, Appl
41	988	91.1	400 16 US-10-410-997-46	Sequence 46, Appl
42	988	91.1	400 16 US-10-411-012-46	Sequence 46, Appl
43	988	91.1	400 16 US-10-287-994-46	Sequence 46, Appl
44	988	91.1	400 16 US-10-410-913-46	Sequence 46, Appl
45	988	91.1	400 17 US-10-410-980-46	Sequence 46, Appl

ALIGNMENTS

RESULT 1

US-10-169-668-5
; Sequence 5, Application US/10169668
; Publication No. US20030129202A1
; GENERAL INFORMATION:
; APPLICANT: BIONEERX
; APPLICANT: INSERM
; TITLE OF INVENTION: MUTATED HEPATITIS B VIRUS, ITS NUCLEIC ACID AND PROTEIN
; TITLE OF INVENTION: CONSTITUENTS AND USES THEREOF
; FILE REFERENCE: IFB 99 INS HBV
; CURRENT APPLICATION NUMBER: US/10/169,668
; CURRENT FILING DATE: 2002-07-08
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 226
; TYPE: PRT
; ORGANISM: mutated hepatitis B virus mHBV
US-10-169-668-5

Query Match	96.4%	Score 1046;	DB 14;	Length 226;
Best Local Similarity	95.8%	Pred. No. 1.9e-82;		
Matches 181;	Conservative 3;	Mismatches 5;	Indels 0;	Gaps 0;
QY	1	DSMWTSINFLGAGTTVCAGQNSQSPSTNSPSCPTCGYRMWCLRRPILFLPILLCIL	60	
DB	33	DSMWTSINFLGAGTTVCAGQNSQSPSTNSPSCPTCGYRMWCLRRPILFLPILLCIL	92	
QY	61	FLVTLVDYQGLPFCPLPGSSSTSKGQCRCTTTPAGSTMYPSGCCCKPBDGNTCTCPI	120	
DB	93	FLVTLVDYQGLPFCPLPGSSSTSKGQCRCTTTPAGSTMYPSGCCCKPBDGNTCTCPI	152	
QY	121	PSNAFGKTLKEMASARESTSLVFPQWFGVLSPTVTLGVIMMMYMGPSLYLSLSPF	180	

Db 213 LPLPIFFC 221

RESULT 5

US-10-104-966-10
Sequence 10, Application US/10104966
Publication No. US20020155124A1

GENERAL INFORMATION:

APPLICANT: Matti Salberg
APPLICANT: Catharina Hultgren
TITLE OF INVENTION: VACCINES CONTAINING RIBAVIRIN AND
TITLE OF INVENTION: METHODS OF USE THEREOF
FILE REFERENCE: TRIPEP.23AUSC1CURRENT APPLICATION NUMBER: US/10/104,966
CURRENT FILING DATE: 2002-03-22PRIOR APPLICATION NUMBER: 09/705,547
PRIOR FILING DATE: 2000-11-03PRIOR APPLICATION NUMBER: 60/229,175
PRIOR FILING DATE: 2000-08-29

NUMBER OF SEQ ID NOS: 15

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 10

LENGTH: 226

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Hepatitis B virus S antigen (HBsAg) sequence

US-10-104-966-10

Query Match 95.9%; Score 1040; DB 13; Length 226;

Best Local Similarity 95.8%; Pred. No. 6.3e-82;

Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

Db 213 LPLPIFFC 221

Query 1 DSWTSLNPLGCTTVCCLGQNSQSPSNTSPSCPTCGYRMCLRRPIIFILLCL 60

Db 33 DSWTSLNPLGCTTVCCLGQNSQSPSNTSPSCPTCGYRMCLRRPIIFILLCL 92

Query 61 FLVLLDYQGLPVCPPLPGSSTTSKQCRCTTTPAOGTSMYPSCCCTKPSDGNCTCPI 120

Db 93 FLVLLDYQGLPVCPPLPGSSTTSKQCRCTTTPAOGTSMYPSCCCTKPSDGNCTCPI 152

Query 121 PSSNAFGKXLMEMASARFWSLSLVPVQWFGSLPTWLSTVIMMMWGPGLYSILSPF 180

Db 153 PSSNAFGKXLMEMASARFWSLSLVPVQWFGSLPTWLSTVIMMMWGPGLYSILSPF 212

Query 181 SPLPIFFC 189

Db 213 LPLPIFFC 221

RESULT 6

US-10-719-619-10

Sequence 10, Application US/10719619

Publication No. US20040086529A1

GENERAL INFORMATION:

APPLICANT: Matti Salberg
APPLICANT: Catharina Hultgren
TITLE OF INVENTION: VACCINES CONTAINING RIBAVIRIN AND
TITLE OF INVENTION: METHODS OF USE THEREOF
FILE REFERENCE: TRIPEP.23AUSC1CURRENT APPLICATION NUMBER: US/10/719,619
CURRENT FILING DATE: 2003-11-20PRIOR APPLICATION NUMBER: 10/104,966
PRIOR FILING DATE: 2002-03-22PRIOR APPLICATION NUMBER: 09/705,547
PRIOR FILING DATE: 2000-11-03PRIOR APPLICATION NUMBER: 60/229,175
PRIOR FILING DATE: 2000-08-29

NUMBER OF SEQ ID NOS: 15

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 10

LENGTH: 226

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Hepatitis B virus S antigen (HBsAg) sequence

GENERAL INFORMATION:

APPLICANT: Matti Salberg
APPLICANT: Catharina Hultgren
TITLE OF INVENTION: VACCINES CONTAINING RIBAVIRIN AND
TITLE OF INVENTION: METHODS OF USE THEREOF
FILE REFERENCE: TRIPEP.23AUSC1CURRENT APPLICATION NUMBER: US/10/817,591
CURRENT FILING DATE: 2004-04-02PRIOR APPLICATION NUMBER: 10/719,619
PRIOR FILING DATE: 2003-11-20PRIOR APPLICATION NUMBER: 10/104,966
PRIOR FILING DATE: 2002-03-22PRIOR APPLICATION NUMBER: 09/929,955
PRIOR FILING DATE: 2001-08-15PRIOR APPLICATION NUMBER: 60/225,767
PRIOR FILING DATE: 2000-08-17

NUMBER OF SEQ ID NOS: 49

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 10

LENGTH: 226

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Hepatitis B virus S antigen (HBsAg) sequence

US-10-817-591-10

Query Match 95.9%; Score 1040; DB 16; Length 226;

Best Local Similarity 95.8%; Pred. No. 6.3e-82;

Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

Db 213 LPLPIFFC 221

Query 1 DSWTSLNPLGCTTVCCLGQNSQSPSNTSPSCPTCGYRMCLRRPIIFILLCL 60

Db 33 DSWTSLNPLGCTTVCCLGQNSQSPSNTSPSCPTCGYRMCLRRPIIFILLCL 92

Query 61 FLVLLDYQGLPVCPPLPGSSTTSKQCRCTTTPAOGTSMYPSCCCTKPSDGNCTCPI 120

Db 93 FLVLLDYQGLPVCPPLPGSSTTSKQCRCTTTPAOGTSMYPSCCCTKPSDGNCTCPI 152

Query 121 PSSNAFGKXLMEMASARFWSLSLVPVQWFGSLPTWLSTVIMMMWGPGLYSILSPF 180

Db 153 PSSNAFGKXLMEMASARFWSLSLVPVQWFGSLPTWLSTVIMMMWGPGLYSILSPF 212

Query 181 SPLPIFFC 189

Db 213 LPLPIFFC 221

Db 153 PSSWAFGKFLMEWASARFWSLLVFFVQWFGVLSPTVWLSVIMMMWYWGSPSLYSILSPF 212
Qy 181 SPLLPPIFFC 189
Db 213 LPLLPPIFFC 221

RESULT 8

US-10-472-724-27
; Sequence 27, Application US/10472724
; Publication No. US20040171806A1
; GENERAL INFORMATION:
; APPLICANT: Cid-Arregui, Angel
; APPLICANT: Zur Hausen, Harald
; TITLE OF INVENTION: Modified HPV E6 and E7 genes and proteins useful for vaccination
; FILE REFERENCE: 4121-154
; CURRENT APPLICATION NUMBER: US/10/472,724
; CURRENT FILING DATE: 2003-09-17
; PRIOR APPLICATION NUMBER: PCT/EP02/03271
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: EP 01107271.7
; PRIOR FILING DATE: 2001-03-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 27
; LENGTH: 227
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic gene EHBs Ag-S-F
US-10-472-724-27

Query Match 95.9%; Score 1040; DB 16; Length 227;
Best Local Similarity 95.8%; Pred. No. 6.3e-82;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
Qy 1 DSWWTSLNFLGGTTVCLGQNSQSPSTNSHSPSCPTCPGYRWMLRRRIIFLFIILLCLLI 60
Db 32 DSWWTSLNFLGGTTVCLGQNSQSPSTNSHSPSCPTCPGYRWMLRRRIIFLFIILLCLLI 91
Qy 61 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRTCTTPAQGTSMPYSCCCTKPSDGNCTCPI 120
Db 92 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRTCTTPAQGTSMPYSCCCTKPSDGNCTCPI 151
Qy 121 PSSWAFGKFLMEWASARFWSLLVFFVQWFGVLSPTVWLSVIMMMWYWGSPSLYSILSPF 180
Db 152 PSSWAFGKFLMEWASARFWSLLVFFVQWFGVLSPTVWLSVIMMMWYWGSPSLYSILSPF 211
Qy 181 SPLLPPIFFC 189
Db 212 LPLLPPIFFC 220

RESULT 9

US-10-371-525-16
; Sequence 16, Application US/10371525
; Publication No. US20030203869A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John D.
; APPLICANT: Hermanson, Gary G.
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn Y.
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert W.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Expression Vectors for Stimulating an
; FILE REFERENCE: 39563-20022.01
; CURRENT APPLICATION NUMBER: US/10/371,525
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 09/311,784
; PRIOR FILING DATE: 1999-05-13

; PRIOR APPLICATION NUMBER: US 60/085,751
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 16
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PADRE-HBV-s
US-10-371-525-16

Query Match 95.9%; Score 1040; DB 15; Length 249;
Best Local Similarity 95.8%; Pred. No. 6.9e-82;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
Qy 1 DSWWTSLNFLGGTTVCLGQNSQSPSTNSHSPSCPTCPGYRWMLRRRIIFLFIILLCLLI 60
Db 56 DSWWTSLNFLGGTTVCLGQNSQSPSTNSHSPSCPTCPGYRWMLRRRIIFLFIILLCLLI 115
Qy 61 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRTCTTPAQGTSMPYSCCCTKPSDGNCTCPI 120
Db 116 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRTCTTPAQGTSMPYSCCCTKPSDGNCTCPI 175
Qy 121 PSSWAFGKFLMEWASARFWSLLVFFVQWFGVLSPTVWLSVIMMMWYWGSPSLYSILSPF 180
Db 176 PSSWAFGKFLMEWASARFWSLLVFFVQWFGVLSPTVWLSVIMMMWYWGSPSLYSILSPF 235
Qy 181 SPLLPPIFFC 189
Db 236 LPLLPPIFFC 244

RESULT 10

US-10-371-069-16
; Sequence 16, Application US/10371069
; Publication No. US20030216342A1
; GENERAL INFORMATION:
; APPLICANT: Epimmune Inc.
; APPLICANT: Fikes, John D.
; APPLICANT: Hermanson, Gary G.
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn Y.
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert W.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Expression Vectors for Stimulating an
; FILE REFERENCE: 39563-20022.10
; CURRENT APPLICATION NUMBER: US/10/371,069
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 09/078,904
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: US 60/085,751
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 16
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PADRE-HBV-s
US-10-371-069-16

Query Match 95.9%; Score 1040; DB 15; Length 249;
Best Local Similarity 95.8%; Pred. No. 6.9e-82;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
Qy 1 DSWWTSLNFLGGTTVCLGQNSQSPSTNSHSPSCPTCPGYRWMLRRRIIFLFIILLCLLI 60
Db 56 DSWWTSLNFLGGTTVCLGQNSQSPSTNSHSPSCPTCPGYRWMLRRRIIFLFIILLCLLI 115

Db 61 FLVLVLDYQGIIPVCPILPGSSSTTSKGCRTCTTPAOGTSMYPSCCCTPSDNCCTCIP1 120
116 FLVLVLDYQGIIPVCPILPGSSSTTSKGCRTCTTPAOGTSMYPSCCCTPSDNCCTCIP1 175
Qy 121 PSSWAFGKILMEWASARFWSLSLVPVQWFGVLSPTVWLSVIMWMMYWGPSLSYLSISPF 180
176 PSSWAFGKILMEWASARFWSLSLVPVQWFGVLSPTVWLSVIMWMMYWGPSLSYLSISPF 235
Qy 181 SPLPIFFC 189
Db 236 LPLPIFFC 244

RESULT 11
US-10-371-645-16
Sequence 16, Application US/10371645
Publication No. US20030216343A1
GENERAL INFORMATION:
APPLICANT: EPIMUNE Inc.
APPLICANT: Fikes, John D.
APPLICANT: Hermanson, Gary G.
APPLICANT: Sette, Alessandro
APPLICANT: Ishioke, Glenn Y.
APPLICANT: Livingston, Brian
APPLICANT: Cheesnut, Robert W.
APPLICANT: Epimmune Inc.
TITLE OF INVENTION: Expression Vectors for Stimulating an
TITLE OF INVENTION: Immune Response and Methods of Using the Same
FILE REFERENCE: 39963-2002.11
CURRENT APPLICATION NUMBER: US/10/371,645
CURRENT FILING DATE: 2003-06-20
PRIOR APPLICATION NUMBER: US 09/078,904
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: US 60/085,751
PRIOR FILING DATE: 1998-05-15
NUMBER OF SEQ ID NOS: 463
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 16
LENGTH: 249
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PADRR-HBV-s
US-10-371-645-16

Query Match 95.9%; Score 1040; DB 15; Length 249;
Best Local Similarity 95.8%; Pred. No. 6.9e-82;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
Qy 1 DSWMTSLNPLFGTTCVCLGNSQSPHSNHSPTSCPTCCGYRMCLRRFIIFILLCL1 60
Db 56 DSWMTSLNPLFGTTCVCLGNSQSPHSNHSPTSCPTCCGYRMCLRRFIIFILLCL1 115
Qy 61 FLVLVLDYQGIIPVCPILPGSSSTTSKGCRTCTTPAOGTSMYPSCCCTPSDNCCTCIP1 120
Db 116 FLVLVLDYQGIIPVCPILPGSSSTTSKGCRTCTTPAOGTSMYPSCCCTPSDNCCTCIP1 175
Qy 121 PSSWAFGKILMEWASARFWSLSLVPVQWFGVLSPTVWLSVIMWMMYWGPSLSYLSISPF 180
Db 176 PSSWAFGKILMEWASARFWSLSLVPVQWFGVLSPTVWLSVIMWMMYWGPSLSYLSISPF 235
Qy 181 SPLPIFFC 189
Db 236 LPLPIFFC 244

RESULT 12
US-10-371-260-16
Sequence 16, Application US/10371260
Publication No. US20030220285A1
GENERAL INFORMATION:
APPLICANT: EPIMUNE Inc.
APPLICANT: Fikes, John D.

APPLICANT: Hermanson, Gary G.
APPLICANT: Sette, Alessandro
APPLICANT: Ishioke, Glenn Y.
APPLICANT: Livingston, Brian
APPLICANT: Cheesnut, Robert W.
APPLICANT: Epimmune Inc.
TITLE OF INVENTION: Expression Vectors for Stimulating an
TITLE OF INVENTION: Immune Response and Methods of Using the Same
FILE REFERENCE: 39963-2002.13
CURRENT APPLICATION NUMBER: US/10/371,260
CURRENT FILING DATE: 2003-02-21
PRIOR APPLICATION NUMBER: US 09/078,904
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: US 60/085,751
PRIOR FILING DATE: 1998-05-15
NUMBER OF SEQ ID NOS: 463
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 16
LENGTH: 249
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PADRR-HBV-s
US-10-371-260-16

Query Match 95.9%; Score 1040; DB 15; Length 249;
Best Local Similarity 95.8%; Pred. No. 6.9e-82;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
Qy 1 DSWMTSLNPLFGTTCVCLGNSQSPHSNHSPTSCPTCCGYRMCLRRFIIFILLCL1 60
Db 56 DSWMTSLNPLFGTTCVCLGNSQSPHSNHSPTSCPTCCGYRMCLRRFIIFILLCL1 115
Qy 61 FLVLVLDYQGIIPVCPILPGSSSTTSKGCRTCTTPAOGTSMYPSCCCTPSDNCCTCIP1 120
Db 116 FLVLVLDYQGIIPVCPILPGSSSTTSKGCRTCTTPAOGTSMYPSCCCTPSDNCCTCIP1 175
Qy 121 PSSWAFGKILMEWASARFWSLSLVPVQWFGVLSPTVWLSVIMWMMYWGPSLSYLSISPF 180
Db 176 PSSWAFGKILMEWASARFWSLSLVPVQWFGVLSPTVWLSVIMWMMYWGPSLSYLSISPF 235
Qy 181 SPLPIFFC 189
Db 236 LPLPIFFC 244

RESULT 13
US-09-247-890-12
Sequence 12, Application US/09247890
Publication No. US20020198162A1
GENERAL INFORMATION:
APPLICANT: Punnonen, Juha
APPLICANT: Bass, Steven H.
APPLICANT: Whalen, Robert Gerald
APPLICANT: Howard, Russell
APPLICANT: Stemmer, Willem P.C.
APPLICANT: Maxygen, Inc.
TITLE OF INVENTION: Antigen Library Immunization
FILE REFERENCE: 018097-028710US
CURRENT APPLICATION NUMBER: US/09/247,890
CURRENT FILING DATE: 1999-02-10
PRIOR APPLICATION NUMBER: US 60/074,294
PRIOR FILING DATE: 1998-02-11
EARLIER APPLICATION NUMBER: US 60/105,509
EARLIER FILING DATE: 1998-10-23
NUMBER OF SEQ ID NOS: 25
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 12
LENGTH: 281
TYPE: PRT
ORGANISM: Hepatitis B virus
US-09-247-890-12

Mon Jul 25 17:03:30 2005

us-09-823-077c-7.rapb

Query Match 95.9%; Score 1040; DB 9; Length 281;
Best Local Similarity 95.8%; Pred. No. 7.8e-82;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

1 DSWMTSLNFIAGTTVCLGNSQSPSTNSHPTSCPTCPGTRMCLRRFIIFILLICLI 60
88 DSWMTSLNFIAGTTVCLGNSQSPSTNSHPTSCPTCPGTRMCLRRFIIFILLICLI 147
61 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRCTTPAOGTSMYPSCCCTKPSDGNCTCIP 120
148 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRCTTPAOGTSMYPSCCCTKPSDGNCTCIP 207
121 PSSWAFGKYLMEWASARFWSLTVPVQWFGVLSPTVWLSVIMWMYWGPSLYSLSPF 180
208 PSSWAFGKYLMEWASARFWSLTVPVQWFGVLSPTVWLSVIMWMYWGPSLYSLSPF 267
181 SPLLPFFC 189
268 LPLLPFFC 276

RESULT 14
US-10-383-317-12
Sequence 12, Application US/10383317
Publication No. US2004001849A1
GENERAL INFORMATION:
APPLICANT: Punnonen, Juh
APPLICANT: Baas, Steven H.
APPLICANT: Whalen, Robert Gerald
APPLICANT: Howard, Russell
APPLICANT: Stemmer, Willem P. C.
APPLICANT: Maxygen, Inc.
TITLE OF INVENTION: Antigen library Immunization
FILE REFERENCE: 018097-028710US
CURRENT APPLICATION NUMBER: US/10/383,317
CURRENT FILING DATE: 2003-03-07
PRIOR APPLICATION NUMBER: US/09/247,890
PRIOR FILING DATE: 1999-02-10
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/074,294
PRIOR FILING DATE: EARLIER FILING DATE: 1998-02-11
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/105,509
PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-23
NUMBER OF SEQ ID NOS: 25
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 12
LENGTH: 281
TYPE: PRT
ORGANISM: Hepatitis B virus
US-10-383-317-12

Query Match 95.9%; Score 1040; DB 15; Length 281;
Best Local Similarity 95.8%; Pred. No. 7.8e-82;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

1 DSWMTSLNFIAGTTVCLGNSQSPSTNSHPTSCPTCPGTRMCLRRFIIFILLICLI 60
88 DSWMTSLNFIAGTTVCLGNSQSPSTNSHPTSCPTCPGTRMCLRRFIIFILLICLI 147
61 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRCTTPAOGTSMYPSCCCTKPSDGNCTCIP 120
148 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRCTTPAOGTSMYPSCCCTKPSDGNCTCIP 207
121 PSSWAFGKYLMEWASARFWSLTVPVQWFGVLSPTVWLSVIMWMYWGPSLYSLSPF 180
208 PSSWAFGKYLMEWASARFWSLTVPVQWFGVLSPTVWLSVIMWMYWGPSLYSLSPF 267
181 SPLLPFFC 189
268 LPLLPFFC 276

Sequence 10, Application US/10472724
Publication No. US20040171806A1
GENERAL INFORMATION:
APPLICANT: Cid-Arregui, Angel
APPLICANT: Zur Hausen, Harald
TITLE OF INVENTION: Modified HPV B6 and E7 genes and proteins useful for vaccination
FILE REFERENCE: 4121-154
CURRENT APPLICATION NUMBER: US/10/472,724
CURRENT FILING DATE: 2003-09-17
PRIOR APPLICATION NUMBER: PCT/EP02/03271
PRIOR FILING DATE: 2002-03-22
PRIOR APPLICATION NUMBER: EP 01107271.7
PRIOR FILING DATE: 2001-03-23
NUMBER OF SEQ ID NOS: 27
SOFTWARE: PatentIn version 3.2
SEQ ID NO 10
LENGTH: 334
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURES:
OTHER INFORMATION: Synthetic Construct
US-10-472-724-10

Query Match 95.9%; Score 1040; DB 16; Length 334;
Best Local Similarity 95.8%; Pred. No. 9.2e-82;
Matches 181; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

1 DSWMTSLNFIAGTTVCLGNSQSPSTNSHPTSCPTCPGTRMCLRRFIIFILLICLI 60
33 DSWMTSLNFIAGTTVCLGNSQSPSTNSHPTSCPTCPGTRMCLRRFIIFILLICLI 92
61 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRCTTPAOGTSMYPSCCCTKPSDGNCTCIP 120
93 FLVLLDYQGLPVCPLIPGSSSTTSKGQCRCTTPAOGTSMYPSCCCTKPSDGNCTCIP 152
121 PSSWAFGKYLMEWASARFWSLTVPVQWFGVLSPTVWLSVIMWMYWGPSLYSLSPF 180
153 PSSWAFGKYLMEWASARFWSLTVPVQWFGVLSPTVWLSVIMWMYWGPSLYSLSPF 212
181 SPLLPFFC 189
213 LPLLPFFC 221

Search completed: July 25, 2005, 11:38:01
Job time : 158 secs